Lighting Science (LSCG) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 07, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'LSCG	'
Entity Registrant Name	'LIGHTING SCIENCE GROUP CORP	'
Entity Central Index Key	'0000866970	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	209,946,697

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$1,238,030	$11,195,412
Restricted cash	3,000,000	5,000,000
Accounts receivable, net	13,290,690	7,771,623
Inventories	21,616,084	19,061,119
Prepaid expenses	3,188,034	1,900,025
Other current assets	1,478,957	358,740
Total current assets	43,811,795	45,286,919
Property and equipment, net	3,217,701	6,498,605
Intangible assets, net	2,482,288	1,850,411
Pegasus Commitment	1,040,000	1,407,335
Debt issuance costs, less current portion	3,516,719	113,283
Other long-term assets	153,442	140,573
Total assets	54,221,945	55,297,126
Current liabilities:	'	'
Lines of credit	12,155,253	40,211,429
Current portion of long-term debt	5,397	4,998
Accounts payable	17,026,370	15,980,466
Provision for losses on non-cancelable purchase commitments	241,641	1,629,806
Accrued expenses	8,952,908	7,180,108
Total current liabilities	38,381,569	65,006,807
Note payable	27,460,185	'
Long-term debt, less current portion	4,011	8,460
Liabilities under derivative contracts	8,969,789	9,175,046
Total other liabilities	36,433,985	9,183,506
Total liabilities	74,815,554	74,190,313
Redeemable Convertible Preferred Stock	442,906,776	391,956,776
Commitments and contingencies	'	'
Stockholders' deficit:	'	'
Preferred stock, $.001 par value, authorized 25,000,000 shares, 113,609 shares of Series H, 62,365 shares of Series I and 45,475 shares of Series J issued and outstanding as of September 30, 2014 and 113,609 shares of Series H, 62,365 shares of Series I and 20,000 shares of Series J issued and outstanding as of December 31, 2013	0	0
Common stock, $.001 par value, authorized 975,000,000 shares, 212,448,631 and 210,349,168 shares issued as of September 30, 2014 and December 31, 2013, respectively	212,449	210,349
Additional paid-in capital	332,161,145	331,199,891
Accumulated deficit	-788,558,955	-734,733,900
Accumulated other comprehensive loss	-3,557,524	-3,768,803
Treasury stock, 2,505,000 shares as of September 30, 2014 and December 31, 2013, at cost	-3,757,500	-3,757,500
Total stockholders' deficit	-463,500,385	-410,849,963
Total liabilities and stockholders' deficit	54,221,945	55,297,126
Series H Redeemable Convertible Preferred Stock [Member]	'	'
Current liabilities:	'	'
Redeemable Convertible Preferred Stock	227,220,149	227,220,149
Series I Redeemable Convertible Preferred Stock [Member]	'	'
Current liabilities:	'	'
Redeemable Convertible Preferred Stock	124,736,627	124,736,627
Series J Redeemable Convertible Preferred Stock [Member]	'	'
Current liabilities:	'	'
Redeemable Convertible Preferred Stock	90,950,000	40,000,000
Stockholders' deficit:	'	'
Additional paid-in capital	$66,600,000	'

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
			Series H Redeemable Convertible Preferred Stock [Member]	Series H Redeemable Convertible Preferred Stock [Member]	Series I Redeemable Convertible Preferred Stock [Member]	Series I Redeemable Convertible Preferred Stock [Member]	Series J Redeemable Convertible Preferred Stock [Member]	Series J Redeemable Convertible Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000	135,000	135,000	90,000	90,000	70,000	70,000
Common stock, par value	$0.00	$0.00	'	'	'	'	'	'
Preferred stock, shares issued	'	'	113,609	113,609	62,365	62,365	45,475	20,000
Common stock, shares authorized	975,000,000	975,000,000	'	'	'	'	'	'
Preferred stock, shares outstanding	'	'	113,609	113,609	62,365	62,365	45,475	20,000
Common stock shares issued	212,448,631	210,349,168	'	'	'	'	'	'
Treasury stock, shares	2,505,000	2,505,000	'	'	'	'	'	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue	$23,089,356	$21,951,094	$68,843,061	$61,925,643
Cost of goods sold (exclusive of depreciation shown below)	19,669,003	27,261,065	61,612,651	64,973,577
Gross profit (deficit)	3,420,353	-5,309,971	7,230,410	-3,047,934
Operating expense:	'	'	'	'
Selling, distribution and administrative (includes related party expenses of $11,000 and $656,000 for the three months ended September 30, 2014 and 2013, and $880,000 and $1.8 million for the nine months ended September 30, 2014 and 2013, respectively)	8,385,811	11,749,901	27,679,750	38,171,922
Research and development	1,099,010	2,630,137	4,177,616	7,774,273
Restructuring expense	2,466,505	55,275	2,672,350	184,107
Depreciation and amortization	615,879	2,594,396	2,692,202	6,886,110
Total operating expenses	12,567,205	17,029,709	37,221,918	53,016,412
Loss from operations	-9,146,852	-22,339,680	-29,991,508	-56,064,346
Other income (expense):	'	'	'	'
Interest income	2,839	1,315	3,475	3,643
Interest expense	-1,494,926	-1,097,141	-4,779,245	-2,943,723
Related party interest expense	-138,300	'	-338,067	'
(Increase) decrease in fair value of liabilities under derivative contracts	8,813,540	-2,116,824	-18,682,848	1,320,753
Other (expense) income, net	-138,877	49,203	-36,862	-35,362
Total other income (expense)	7,044,276	-3,163,447	-23,833,547	-1,654,689
Loss before income tax expense	-2,102,576	-25,503,127	-53,825,055	-57,719,035
Income tax expense	'	'	'	'
Net loss	-2,102,576	-25,503,127	-53,825,055	-57,719,035
Foreign currency translation gain (loss)	60,574	130,601	211,279	-107,179
Comprehensive loss	($2,042,002)	($25,372,526)	($53,613,776)	($57,826,214)
Controlling Shareholders [Member]	'	'	'	'
Other income (expense):	'	'	'	'
Basic and diluted net loss per weighted average common share	($0.04)	($0.30)	($0.35)	($0.46)
Basic and diluted weighted average number of common shares outstanding	255,194,735	170,672,339	220,629,709	170,645,985
Noncontrolling Shareholders [Member]	'	'	'	'
Other income (expense):	'	'	'	'
Basic and diluted net loss per weighted average common share	($0.04)	($0.30)	($0.36)	($0.46)
Basic and diluted weighted average number of common shares outstanding	63,038,781	35,062,174	53,029,108	34,996,177

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) (Selling, Distribution and Administrative Expenses [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Selling, Distribution and Administrative Expenses [Member]	'	'	'	'
Related party expense	$11,000	$656,000	$880,000	$1,800,000

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Deficit (Unaudited) (USD $)

Total

Series J Redeemable Convertible Preferred Stock [Member]

Pegasus Warrant [Member]

Series J Warrants [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Accumulated Other Comprehensive Loss [Member]

Treasury Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Pegasus Warrant [Member]

Series J Warrants [Member]

Balance at Dec. 31, 2013

($410,849,963)

'

'

'

$210,349

$331,199,891

'

'

'

($734,733,900)

($3,768,803)

($3,757,500)

Balance, shares at Dec. 31, 2013

'

'

'

'

210,349,168

'

'

'

'

'

'

'

Issuance of restricted stock and options for directors' compensation

412,451

'

'

'

1,751

410,700

'

'

'

'

'

'

Issuance of restricted stock and options for directors' compensation, shares

'

'

'

'

1,750,342

'

'

'

'

'

'

'

Stock based compensation expense

1,901,285

'

'

'

330

1,900,955

'

'

'

'

'

'

Stock based compensation expense, shares

'

'

'

'

330,000

'

'

'

'

'

'

'

Stock issued under equity compensation plans

5,462

'

'

'

19

5,443

'

'

'

'

'

'

Stock issued under equity compensation plans, shares

'

'

'

'

19,121

'

'

'

'

'

'

'

Warrant issued to a customer

-13,055

'

'

3,849,742

'

-13,055

'

'

3,849,742

'

'

'

Deemed dividends on Series J Redeemable Convertible Preferred Stock

'

-42,268,257

'

'

'

'

-42,268,257

'

'

'

'

'

Series J Warrants reclassified from liability to equity

'

'

'

37,646,300

'

'

'

'

37,646,300

'

'

'

Deemed dividend for issuance of Pegasus Guaranty Warrants

'

'

-570,574

'

'

'

'

-570,574

'

'

'

'

Net loss

-53,825,055

'

'

'

'

'

'

'

'

-53,825,055

'

'

Foreign currency translation adjustment

211,279

'

'

'

'

'

'

'

'

'

211,279

'

Balance at Sep. 30, 2014

($463,500,385)

'

'

'

$212,449

$332,161,145

'

'

'

($788,558,955)

($3,557,524)

($3,757,500)

Balance, shares at Sep. 30, 2014

'

'

'

'

212,448,631

'

'

'

'

'

'

'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($53,825,055)	($57,719,035)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	2,692,202	6,886,110
Impairment of plant and equipment	41,555	1,328
Issuance of restricted stock and stock options for directors' compensation	412,451	259,724
Stock based compensation expense	1,901,285	4,850,527
Non-cash sales incentive	99,801	22,916
Allowance for doubtful accounts receivable	25,672	130,438
Write-down of inventory	1,491,365	5,697,809
Provision for losses on non-cancelable purchase commitments	-373,623	1,908,694
Increase (decrease) in fair value of derivative contracts	18,682,848	-1,320,753
Amortization of debt issuance costs	1,299,931	394,329
Medley discount accretion	473,935	0
Interest accrued on Medley Term Loan	381,611	0
Loss on disposal of assets	639,490	497,140
Changes in operating assets and liabilities:	'	'
Accounts receivable	-5,520,513	2,998,530
Inventories	-5,060,872	-8,262,220
Prepaid expenses	-1,287,842	873,962
Other current and long-term assets	139,753	156,838
Accounts payable	1,056,734	-4,530,892
Accrued expenses and other liabilities	1,790,940	-2,625,304
Net cash used in operating activities	-34,938,332	-49,779,859
Cash flows from investing activities:	'	'
Purchases of property and equipment	-420,116	-1,486,067
Capitalized patents	-687,079	-772,322
Proceeds from sale of property and equipment	383,159	565,918
Net cash used in investing activities	-724,036	-1,692,471
Cash flows from financing activities:	'	'
Net (payments) proceeds from draws on lines of credit and other short-term borrowings	-28,056,176	29,009,826
Proceeds from notes payable	29,775,000	0
Payment of short and long-term debt	-4,050	-3,666
Debt issuance costs	-3,210,206	0
Decrease in restricted cash related to line of credit	2,000,000	0
Proceeds from issuance of common stock under equity compensation plans	5,462	35,913
Proceeds from issuance of Series J Redeemable Convertible Preferred Securities	25,475,000	17,394,000
Fees incurred on private placements	-437,776	-556,049
Net cash provided by financing activities	25,547,254	45,880,024
Effect of exchange rate changes on cash	157,732	50,753
Net decrease in cash	-9,957,382	-5,541,553
Cash and cash equivalents balance at beginning of period	11,195,412	15,834,077
Cash and cash equivalents balance at end of period	1,238,030	10,292,524
Supplemental disclosures:	'	'
Interest paid during the period	3,753,932	2,878,583
Non-cash investing and financing activities:	'	'
Fair value of Pegasus Guaranty included in debt issuance costs	6,000,000	'
Series J Warrants [Member]	'	'
Non-cash investing and financing activities:	'	'
Reclass of Series J Warrants from liabilities to equity	37,646,300	'
Issuance of Series J Warrants	3,849,742	'
THD Warrant [Member]	'	'
Non-cash investing and financing activities:	'	'
Reclass of THD Warrant from equity to liabilities	-74,576	'
Pegasus Guaranty [Member]	'	'
Non-cash investing and financing activities:	'	'
Fair value of Pegasus Guaranty included in debt issuance costs	-2,766,000	'
Series J Redeemable Convertible Preferred Stock [Member]	'	'
Non-cash investing and financing activities:	'	'
Deemed dividends	-42,268,257	-21,590,049
Pegasus Guaranty Warrants [Member]	'	'
Non-cash investing and financing activities:	'	'
Deemed dividends	($570,574)	'

Description_of_Business_and_Ba

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Description of Business and Basis of Presentation	'
	NOTE 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
	Overview
	Lighting Science Group Corporation (the “Company”) was incorporated in Delaware in 1988 and designs, develops, manufactures and markets general illumination products that exclusively use light emitting diodes (“LEDs”) as their light source. The Company’s product portfolio includes LED-based retrofit lamps (replacement bulbs) that can be used in existing light fixtures and sockets as well as purpose built LED-based luminaires (light fixtures) for many common indoor and outdoor residential, commercial, industrial and public infrastructure lighting applications. The Company assembles and manufactures products internally and through its contract manufacturers in Asia.
	Basis of Financial Statement Presentation
	The accompanying unaudited condensed consolidated financial statements are presented pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) in accordance with the disclosure requirements for the quarterly report on Form 10-Q and therefore do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to fairly state the results for the interim periods presented. The condensed consolidated balance sheet as of December 31, 2013 is derived from the Company’s audited financial statements. Operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results of the Company that may be expected for the year ending December 31, 2014. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2013 and notes thereto included in the Company’s Annual Report on Form 10-K/A originally filed with the SEC on April 10, 2014.
	The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the accompanying consolidated financial statements.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. The Company’s actual results could differ from these estimates.
	Restricted Cash
	As of September 30, 2014, as required by the Company’s five-year term loan (the “Medley Term Loan”) with Medley Capital Corporation (“Medley”), the Company was required to maintain a minimum restricted cash balance of $3.0 million to collateralize the Medley Term Loan. As of December 31, 2013, as required by the Company’s asset-based revolving credit facility (as amended, the “Wells Fargo ABL”) with Wells Fargo Bank N.A. (“Wells Fargo”), the Company was required to maintain a minimum qualified cash balance of $5.0 million as a compensating balance against the Wells Fargo ABL. Changes in the restricted cash balance are reflected as a financing activity in the consolidated statement of cash flows.
	Accounts Receivable
	The Company records accounts receivable at the invoiced amount when its products are shipped to customers or when specific milestone billing requirements are completed. The Company’s accounts receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, age of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based on age or customer circumstances, that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of September 30, 2014 and December 31, 2013, the Company’s accounts receivable were reflected net of an allowance for doubtful accounts of $331,000 and $475,000, respectively.
	As of September 30, 2014, $9.2 million of eligible accounts receivable were pledged as collateral for the three year asset based revolving credit facility (the “FCC ABL”) entered into on April 25, 2014 with FCC, LLC d/b/a First Capital (“First Capital”). As of December 31, 2013, $6.8 million of eligible accounts receivable were pledged as collateral for the Wells Fargo ABL.
	Revenue Recognition
	The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once those terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). ASU 2014-09 seeks to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2014-09, but the standard is not expected to have a significant effect on its consolidated financial statements.
	Product Warranties
	The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products. Such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The warranty provision is included in accrued expenses on the condensed consolidated balance sheet. Changes in the warranty provision for the nine months ended September 30, 2014 were as follows:
	Warranty provision as of December 31, 2013	$	3,231,991
	Additions to provision		2,404,970
	Less warranty costs		(2,481,116	)
	Warranty provision as of September 30, 2014	$	3,155,845
	Fair Value of Financial Instruments
	Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and note payable are carried at amounts that approximate their fair value due to the short-term maturity of these instruments and/or variable, market driven interest rates.
	The Riverwood Warrants, September 2012 Warrants and the Pegasus Commitment (each as defined in Note 10 below), the Pegasus Warrant and Series J Warrants, (each as defined in Note 9 below) and the Medley Warrants and Pegasus Guaranty Warrants (each as defined in Note 7 below) were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period. Once a portion of the THD Warrant (as defined in Note 11 below) vests it is recorded at its fair value at the end of each subsequent reporting period.

Liquidity_and_Capital_Resource

Liquidity and Capital Resources	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Liquidity and Capital Resources	'
	NOTE 3. LIQUIDITY AND CAPITAL RESOURCES
	As shown in the condensed consolidated financial statements, the Company has experienced significant net losses as well as negative cash flows from operations since its inception, resulting in an accumulated deficit of $788.6 million and stockholders’ deficit of $463.5 million as of September 30, 2014. The Company’s cash expenditures primarily relate to procurement of inventory, payment of salaries, employee benefits and other operating costs. The Company’s primary sources of liquidity have historically been borrowings from Wells Fargo under the Wells Fargo ABL, which was replaced by the Medley Term Loan in February 2014 and the FCC ABL in April 2014, as well as sales of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and the Company’s preferred stock to, and short-term loans from, affiliates of Pegasus Capital Advisors, L.P. (“Pegasus Capital”), including Pegasus Partners IV, L.P. (“Pegasus IV”), LSGC Holdings LLC (“LSGC Holdings”), LSGC Holdings II LLC (“Holdings II”) and PCA LSG Holdings, LLC (“PCA Holdings” and collectively with Pegasus Capital, Pegasus IV, LSGC Holdings, Holdings II and their affiliates, “Pegasus”). Pegasus is the Company’s controlling stockholder. While Pegasus has led many of the Company’s capital raises, each of the Series H and I Preferred Offering (as defined in Note 10 below), the September 2012 Preferred Offering (as defined in Note 10 below), the Initial Series J Preferred Offering (as defined in Note 9 below) and the Follow-On Series J Offering (as defined in Note 9 below) also involved and/or were led by parties other than Pegasus.
	On February 19, 2014, the Company entered into an agreement with Medley (as amended from time to time the “Medley Loan Agreement”) pursuant to which the Company obtained the five-year, $30.5 million Medley Term Loan and a two-year delayed draw term loan (the “Medley Delayed Draw Loan”). The Company utilized proceeds from the Medley Term Loan to repay its outstanding obligations under the Wells Fargo ABL and the Second Lien Letter of Credit Facility (the “Ares Letter of Credit Facility”), dated September 20, 2011, between the Company and Ares Capital Corporation (“Ares Capital”).
	On April 25, 2014, the Company entered into the FCC ABL, a three-year revolving credit facility with First Capital. The Company utilized proceeds from the FCC ABL to repay its outstanding obligations under the Medley Delayed Draw Loan. The Medley Loan Agreement was amended on April 25, 2014 to, among other things, terminate the Medley Delayed Draw Loan and permit the indebtedness under the FCC ABL. As of September 30, 2014, the Company had $12.2 million outstanding under the FCC ABL and additional borrowing capacity of $6.7 million.
	As of September 30, 2014, the Company had cash and cash equivalents of $1.2 million and an additional $3.0 million in restricted cash subject to a cash collateral dominion agreement pursuant to the Medley Term Loan. The FCC ABL provides the Company with a maximum borrowing capacity of $22.5 million, which capacity is equal to (i) the sum of (A) 85% of the Company’s eligible accounts receivable and (B) the lesser of (a) $10 million and (b) the sum of (x) the lesser of (1) 65% of the dollar value of certain eligible inventory and (2) 85% of the net orderly liquidation value of such eligible inventory, (y) 65% of certain other inventory and (z) the lesser of (1) $4.5 million and (2) the lesser of 65% of the dollar value, or 85% of the net orderly liquidation value, of eligible inventory that is in-transit, minus (ii) the sum of reserves established by First Capital and the aggregate amount of the Company’s outstanding letter of credit obligations (collectively, the “Borrowing Base”). The Company is at all times required to maintain (i) a Borrowing Base that exceeds the amount of its outstanding borrowings under the FCC ABL and (ii) $3.0 million in restricted cash pursuant to the Medley Loan Agreement. The Company is required to comply with certain specified EBITDA requirements, maintain a specified lamp sourcing percentage and comply with maximum capital expenditure limits.
	Commencing on September 25, 2015, Riverwood (as defined in Note 9 below) and Pegasus will have the right to cause the Company to redeem their shares of Series H Preferred Stock and Series I Preferred Stock (each as defined in Note 10 below), respectively. If either Riverwood or Pegasus elects to cause the Company to redeem their shares of Series H Preferred Stock or Series I Preferred Stock, all other holders of the applicable series will have the right to redeem their shares of Preferred Stock. Further, in the event Riverwood so elects to cause such redemption of its Series H Preferred Stock, the holders of shares of Series J Preferred Stock (as defined in Note 9 below) would also have the option to redeem any or all of their shares of Series J Preferred Stock prior to the redemption of the Series H Preferred Stock. In total, the maximum payment obligation of the Company in the event of a redemption of all the Series H, I and J Preferred Stock is $442.9 million. Finally, any such redemption of shares of Series H, I or J Preferred Stock would result in an acceleration of the obligations of the Medley Term Loan and the FCC ABL. As of September 30, 2014, the aggregate borrowings outstanding under each of these loan facilities was $39.6 million.
	The Company continues to face challenges in its efforts to achieve positive cash flows from operations and profitability. The Company’s ability to meet its obligations in the ordinary course of business is dependent upon establishing profitable operations and raising additional capital through public or private financing, as well as the continued support of its existing investors. The Company’s current business plan includes a focus on increasing revenue by updating and expanding its product offerings and capitalizing on the known product needs of its existing customers, as well as improving gross margins by significantly leveraging contract manufacturers in Asia and reducing operating costs, primarily through the restructuring initiated in 2013 and continuing in 2014. The Company may not be able to raise capital in the future on terms that are acceptable to the Company, if at all. In addition, any future financings involving the issuance of the Company’s equity securities may be dilutive to the Company’s current stockholders.
	The Company has historically been dependent on Pegasus and other investors for its liquidity needs because other cash flows from operations have been insufficient to meet the needs of the Company. As disclosed on the Company’s Form 8-K filed with the Securities and Exchange Commission on August 20, 2014, the Company continues to seek to raise additional capital to improve its liquidity and cash positions through the issuance of its Series J Securities on or before December 31, 2014. The Company may seek to raise additional capital from Pegasus in the near term if it is unable to raise capital on acceptable terms from a third-party, however neither Pegasus nor any other person has committed to provide any additional capital to the Company or provided any guarantee that any additional capital will be available to the Company. Any potential investment by Pegasus or any other third-party, may be effected through a variety of mechanisms or securities, which may or may not be similar to those previously employed or issued.

Detail_of_Certain_Balance_Shee

Detail of Certain Balance Sheet Accounts	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Detail of Certain Balance Sheet Accounts	'
	NOTE 4. DETAIL OF CERTAIN BALANCE SHEET ACCOUNTS
	Inventories
	Inventories consisted of the following as of the dates indicated:
		September 30, 2014			December 31, 2013
	Raw materials and components	$	1,631,251		$	6,868,139
	Work-in-process		—			1,599,089
	Finished goods		19,984,833			10,593,891
	Total inventory, net	$	21,616,084		$	19,061,119
	Consigned inventory is held at third-party locations, including those of the Company’s contract manufacturers. The Company retains title to the consigned inventory until such inventory is purchased by a third party. Consigned inventory, consisting of raw materials, was $932,000 and $693,000 as of September 30, 2014 and December 31, 2013, respectively.
	As of September 30, 2014 and December 31, 2013, inventories were stated net of inventory write downs of $9.6 million and $24.1 million, respectively. The Company considered a number of factors in estimating the required inventory write downs, including (i) the focus of the business on the next generation of the Company’s products, which utilize lower cost technologies, (ii) the strategic focus on core products to meet the demands of key customers and (iii) the expected demand for the Company’s current generation of products, which is approaching the end of its lifecycle upon the introduction of the next generation of products.
	Property and Equipment, Net
	Property and equipment, net consisted of the following as of the dates indicated:
		September 30, 2014			December 31, 2013
	Leasehold improvements	$	474,192		$	1,486,628
	Office furniture and equipment		483,139			1,141,314
	Computer hardware and software		8,118,864			8,802,484
	Tooling, production and test equipment		4,446,313			16,141,358
	Trailers		45,996			—
	Construction-in-process		133,396			325,252
	Total property and equipment		13,701,900			27,897,036
	Accumulated depreciation		(10,484,199	)		(21,398,431	)
	Total property and equipment, net	$	3,217,701		$	6,498,605
	Depreciation related to property and equipment was $599,000 and $2.6 million for the three months ended September 30, 2014 and 2013, respectively. Depreciation related to property and equipment was $2.6 million and $6.9 million for the nine months ended September 30, 2014 and 2013, respectively.

Intangible_Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	NOTE 5. INTANGIBLE ASSETS
	Intangible assets that have finite lives are amortized over their useful lives. The Company’s intangible assets as of September 30, 2014 and December 31, 2013 are detailed below:
		Cost, Less		Accumulated			Net Book		Estimated
		Impairment		Amortization			Value		Remaining
		Charges							Useful Life
	September 30, 2014:
	Technology and intellectual property	$	2,688,121	$	(205,833	)	$	2,482,288		2.7 to 20.0 years
	December 31, 2013:
	Technology and intellectual property	$	2,011,654	$	(161,243	)	$	1,850,411		3.2 to 20.0 years
	Total intangible asset amortization expense was $17,000 and $12,000 for the three months ended September 30, 2014 and 2013, respectively. Total intangible asset amortization expense was $46,000 and $27,000 for the nine months ended September 30, 2014 and 2013, respectively.

Debt_Issuance_Costs

Debt Issuance Costs	9 Months Ended
	Sep. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Debt Issuance Costs	'
	NOTE 6. DEBT ISSUANCE COSTS
	The Company capitalizes its costs related to the issuance of long-term debt and amortizes these costs using the effective interest rate method over the life of the loan. Amortization of debt issuance costs and the accelerated write-off of debt issuance costs in connection with refinancing activities are recorded as a component of interest expense. The Company had net debt issuance costs of $4.8 million and $113,000 as of September 30, 2014 and December 31, 2013, respectively. As of September 30, 2014, the current portion of the debt issuance costs was $1.3 million and was included in other current assets. In connection with the FCC ABL, the Medley Delayed Draw Loan and the Medley Term Loan, $6.0 million of debt issuance costs were capitalized, including $2.8 million related to the fair value of the Pegasus Guaranty (as defined in Note 7 below). The Company amortized $312,000 and $117,000 of debt issuance costs for the three months ended September 30, 2014 and 2013, respectively, and $1.3 million and $394,000 of debt issuance costs for the nine months ended September 30, 2014 and 2013, respectively.

Lines_of_Credit_and_Note_Payab

Lines of Credit and Note Payable	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Lines of Credit and Note Payable	'
	NOTE 7. LINES OF CREDIT AND NOTE PAYABLE
	First Capital
	On April 25, 2014, the Company, entered into the FCC ABL, which provides the Company with a maximum borrowing capacity of $22.5 million, which capacity is limited by a Borrowing Base equal to (i) the sum of (A) 85% of the Company’s eligible accounts receivable and (B) the lesser of (a) $10 million and (b) the sum of (x) the lesser of (1) 65% of the dollar value of certain eligible inventory and (2) 85% of the net orderly liquidation value of such eligible inventory, (y) 65% of certain other inventory and (z) the lesser of (1) $4.5 million and (2) the lesser of 65% of the dollar value or 85% of the net orderly liquidation value of eligible inventory that is in-transit, minus (ii) the sum of reserves established by First Capital and the amount of the Company’s outstanding letter of credit obligations. As of September 30, 2014, the Company had $12.2 million outstanding under the FCC ABL and additional borrowing capacity of $6.7 million.
	As of September 30, 2014, eligible collateral included $9.2 million of accounts receivable and $10.0 million of inventory. Borrowings under the FCC ABL bear interest at a floating rate equal to one-month LIBOR plus 4.0% per annum. As of September 30, 2014, the interest rate on the FCC ABL was 4.16%.
	On September 19, 2014, the Company entered into Amendment No. 1 to the FCC ABL, which provides that the entry of a judgment in connection with the Geveran Suit (as defined in Note 16 below) would not constitute a default under the FCC ABL unless it gives rise to the entry or filing of a judgment, order or award for the payment of $250,000 or more (which amount is not covered by insurance) against the Company and (i) within 45 days after the entry of such judgment, order or award (a) such judgment, order or award is not discharged, satisfied, vacated or bonded pending appeal, or (b) a stay of enforcement thereof is not in effect; (ii) enforcement proceedings with respect to such judgment have been commenced, or (iii) any person becomes a lien creditor (as defined in the Uniform Commercial Code) of the Company in connection with the Geveran Suit.
	Medley Delayed Draw Loan
	On February 19, 2014, the Company, entered into the Medley Delayed Draw Loan, which provided the Company with borrowing capacity of up to $22.5 million. The Medley Delayed Draw Loan bore interest at a floating rate equal to three-month LIBOR plus 10.5% per annum. Proceeds from the FCC ABL were used to repay the Company’s outstanding obligations under the Medley Delayed Draw Loan on April 25, 2014.
	Medley Term Loan
	On February 19, 2014, the Company, entered into the Medley Term Loan, which provided the Company with a $30.5 million term loan facility. The Medley Term Loan bears interest at a floating rate equal to three-month LIBOR plus 12% per annum, as follows: (i) up to 2% (at the Company’s election) of interest may be paid as “payment in kind” by adding such accrued interest to the unpaid principal balance of the Medley Term Loan and (ii) the remaining accrued interest amount is payable in cash monthly in arrears. As of September 30, 2014, the interest rate on the Medley Term Loan was 12.24%. Additionally, $3.0 million of the Medley Term Loan was funded directly into a deposit account to which Medley has exclusive access, to further secure the loan. The outstanding principal balance and all accrued and unpaid interest on the Medley Term Loan are due and payable on February 19, 2019. As of September 30, 2014 the balance of the Medley Term Loan was $27.5 million, which included the initial loan balance of $30.5 million offset by a discount of $725,000 related to commitment fees paid to Medley and a discount of $3.2 million related to the Medley Warrants (discussed below). In addition, the Company recognized $474,000 of interest expense for the accretion of the discounts to the balance of the Medley Term Loan related to the commitment fees and the Medley Warrants and $382,000 of accrued interest for the period from February 19, 2014 to September 30, 2014.
	Medley Warrants
	On February 19, 2014, in connection with the Medley Loan Agreement, the Company issued a warrant to purchase 5,000,000 shares of Common Stock to each of Medley and Medley Opportunity Fund II LP (together, the “Medley Warrants”). The Medley Warrants have an exercise price equal to $0.95 and, if unexercised, expire on February 19, 2024. The Medley Warrants became exercisable on April 14, 2014 when the Company amended its Certificate of Incorporation to increase the number of shares of Common Stock authorized for issuance (the “Charter Amendment”).
	The Medley Warrants are considered derivative financial instruments in accordance with ASC 815-10-15, “Derivatives and Hedging” due to the down round protection provided to the holders by the instruments. The Medley Warrants were recorded as a liability at fair value using the Black Scholes valuation method at issuance and were valued at $3.2 million as of February 19, 2014, which was recorded as a discount to the Medley Term Loan. The discount is being accreted using the effective interest rate method over the life of the loan as a non-cash charge to interest expense. Changes in the fair value of the Medley Warrants are measured and recorded at the end of each quarter. The decrease in fair value of the Medley Warrants was $1.7 million for the three months ended September 30, 2014 and $1.8 million for the period from February 19, 2014 (the date of issuance of the Medley Warrants) to September 30, 2014, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss. Accretion of the discount on the Medley Term Loan was $195,000 for the three months ended September 30, 2014 and $474,000 for the period from February 19, 2014 to September 30, 2014 and was included in interest expense.
	On February 19, 2014, the Company also entered into a registration rights agreement with Medley and Medley Opportunity Fund II LP, pursuant to which the Company granted piggyback registration rights with respect to the shares of Common Stock underlying the Medley Warrants and any other shares of Common Stock that may be acquired by such parties in the future.
	Pegasus Guaranty and Pegasus Guaranty Warrants
	Pegasus Capital Partners IV, L.P. and Pegasus Capital Partners V, L.P. (collectively, the “Pegasus Guarantors”) agreed to provide a guaranty of the Company’s obligations under the Medley Loan Agreement in favor of Medley (the “Pegasus Guaranty”). The Pegasus Guaranty was recorded as debt issuance costs at fair value on the date of issuance. The fair value was determined to be $2.8 million as of February 19, 2014, using an implied interest rate analysis. The debt issuance costs will be amortized as non-cash interest expense over the life of the Medley Term Loan. As consideration for the Pegasus Guaranty, on February 19, 2014, the Company issued a warrant to purchase 5,000,000 shares of Common Stock to each of the Pegasus Guarantors (the “Pegasus Guaranty Warrants”). The Pegasus Guaranty Warrants have an exercise price equal to $0.50 and, if unexercised, expire on February 19, 2024. The Pegasus Guaranty Warrants are considered derivative financial instruments in accordance with ASC 815-10-15, “Derivatives and Hedging,” due to the down round protection provided by the instrument. The Pegasus Guaranty Warrants were recorded as a liability at fair value using the Black Scholes valuation method at issuance and were valued at $3.3 million as of February 19, 2014. The fair value of the Pegasus Guaranty partially offset the fair value of the Pegasus Guaranty Warrants, with the remaining value of $571,000 accounted for as a deemed dividend to the Company’s controlling stockholder. Changes in the fair value of the Pegasus Guaranty Warrants are measured and recorded at the end of each quarter. The decrease in fair value of the Pegasus Guaranty Warrants was $1.8 million for the three months ended September 30, 2014 and $1.9 million for the period from February 19, 2014 (the date of issuance of the Pegasus Guaranty Warrants) to September 30, 2014, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss.
	Wells Fargo
	The Wells Fargo ABL provided the Company with borrowing capacity of up to $50.0 million. On February 19, 2014, the Company utilized proceeds from the Medley Term Loan to repay its outstanding obligations under the Wells Fargo ABL.
	Ares Capital
	On September 21, 2011, the Company entered into the Ares Letter of Credit Facility, a $25.0 million standby letter of credit issued by Ares Capital in favor of Wells Fargo for the benefit of the Company. On February 19, 2014, the Company utilized proceeds from the Medley Term Loan to repay its outstanding obligations under the Ares Letter of Credit Facility.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	NOTE 8. FAIR VALUE MEASUREMENTS
	The Fair Value Measurements and Disclosures Topic of the Financial Accounting Standards Board Accounting Standards Codification (“ASC”) defines fair value as the price at which an asset could be exchanged in a current transaction between knowledgeable, willing parties. A liability’s fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor.
	Assets and liabilities measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity associated with the inputs to a fair valuation of these assets and liabilities and are based on (i) unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date (Level 1); (ii) quoted prices in non-active markets or inputs that are observable either directly or indirectly for substantially the full term of the asset or liability (Level 2); and (iii) prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement (Level 3).
	The Company has recorded the Medley Warrants and the Pegasus Guaranty Warrants at their fair values using the Black Scholes valuation method and they are valued on a recurring basis at the end of each reporting period. The Company recorded the Series J Warrants (as defined in Note 9 below) at their fair value using the Black Scholes valuation method on the date of issuance and they were valued on a recurring basis at the end of each reporting period when they were classified as a liability. The Company filed the Charter Amendment to increase the number of shares of Common Stock authorized for issuance, which was effective April 14, 2014. After the Charter Amendment was filed, the Series J Warrants were reclassified as equity instruments. As of April 14, 2014, the Series J Warrants were recorded at their fair value and reclassified from liability to additional paid-in capital, and are no longer valued on a recurring basis as long as they are classified as an equity instrument. The Company has recorded the Pegasus Warrant (as defined in Note 9 below), the Riverwood Warrants, the September 2012 Warrants, the Pegasus Commitment (each as defined in Note 10 below) and the THD Warrant (as defined in Note 11 below) at their fair values using the Monte Carlo valuation method and they are valued on a recurring basis at the end of each reporting period, as long as they are classified as a liability.
	The Pegasus Guaranty was recorded at fair value on a non-recurring basis on the date of issuance using an implied interest rate analysis. The fair value was determined to be $2.8 million as of February 19, 2014 and was included in debt issuance costs.
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2014, according to the valuation techniques the Company used to determine their fair values:
		Fair Value Measurement as of September 30, 2014
		Quoted Price in			Significant Other			Significant
		Active Markets for			Observable Inputs			Unobservable Inputs
		Identical Assets
		Level 1			Level 2			Level 3
	Assets (Recurring):
	Pegasus Commitment	$	—		$	—		$	1,040,000
	Liabilities (Recurring):
	Riverwood Warrants	$	—		$	—		$	3,256,653
	September 2012 Warrants		—			—			1,040,000
	Pegasus Warrant		—			—			1,800,000
	THD Warrant		—			—			114,443
	Medley Warrants		—			—			1,323,312
	Pegasus Guaranty Warrants		—			—			1,435,381
		$	—		$	—		$	8,969,789
	The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the nine months ended September 30, 2014:
		Balance			Realized and unrealized			Purchases, sales,			Transfers in			Balance
		December 31, 2013			gains (losses) included			issuances and			or out of			September 30, 2014
					in net loss			settlements			Level 3
	Pegasus Commitment	$	1,407,335		$	(367,335	)	$	—		$	—		$	1,040,000
	Riverwood Warrants		(5,002,664	)		1,746,011			—			—			(3,256,653	)
	September 2012 Warrants		(1,407,335	)		367,335			—			—			(1,040,000	)
	Pegasus Warrant		(2,765,047	)		965,047			—			—			(1,800,000	)
	THD Warrant		—			(39,867	)		—			(74,576	)		(114,443	)
	Series J Warrants		—			(25,140,561	)		(12,505,739	)		37,646,300			—
	Medley Warrants		—			1,847,049			(3,170,361	)		—			(1,323,312	)
	Pegasus Guaranty Warrants		—			1,901,193			(3,336,574	)		—			(1,435,381	)
	Total	$	(7,767,711	)	$	(18,721,128	)	$	(19,012,674	)	$	37,571,724		$	(7,929,789	)
	The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the nine months ended September 30, 2013:
		Balance			Realized and unrealized			Purchases, sales,			Transfers in			Balance
		December 31, 2012			gains (losses) included			issuances and			or out of			September 30, 2013
					in net loss			settlements			Level 3
	Pegasus Commitment	$	1,360,000		$	240,000		$	—		$	—		$	1,600,000
	Riverwood Warrants		(7,960,705	)		1,320,753			—			—			(6,639,952	)
	September 2012 Warrants		(1,360,000	)		(240,000	)		—			—			(1,600,000	)
	Pegasus Warrant		—			—			(3,700,000	)		—			(3,700,000	)
	Total	$	(7,960,705	)	$	1,320,753		$	(3,700,000	)	$	—		$	(10,339,952	)

Series_J_Redeemable_Convertibl

Series J Redeemable Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Series J Redeemable Convertible Preferred Stock	'
	NOTE 9. SERIES J REDEEMABLE CONVERTIBLE PREFERRED STOCK
	Initial Series J Preferred Offering
	From September 11, 2013 through November 18, 2013, the Company issued an aggregate of 20,000 shares of its Series J Preferred Stock, par value $0.001 per share (the “Series J Preferred Stock”), at a price of $1,000 per share (the “Stated Value”) for aggregate proceeds of $20.0 million (the “Initial Series J Preferred Offering”). The shares of Series J Preferred Stock were issued pursuant to a preferred stock subscription agreement among the Company, PCA Holdings, Holdings II and RW LSG Holdings LLC, (“Riverwood Holdings”), an affiliate of Riverwood LSG Management Holdings LLC (“Riverwood Management”) and Riverwood Capital Partners L.P. (“Riverwood Capital,” and collectively with Riverwood Holdings, Riverwood Management and their affiliates, “Riverwood”). The Company issued 13,657; 2,500; 2,394 and 1,449 shares of Series J Preferred Stock to Holdings II, PCA Holdings, Riverwood Holdings and other accredited investors, respectively (the “Initial Series J Investors”). As compensation for advisory services provided by Pegasus, on September 11, 2013 the Company issued a warrant to Holdings II (the “Pegasus Warrant”), representing the right to purchase 10,000,000 shares of Common Stock at a variable exercise price that will be determined on the date of exercise of the Pegasus Warrant.
	The Series J Preferred Stock is senior to the Series H Preferred Stock (as defined in Note 10 below), the Series I Preferred Stock (as defined in Note 10 below) and the Common Stock and is entitled to dividends of the same type as any dividends or other distribution of any kind payable or to be made on outstanding shares of Common Stock, on an as converted basis. Each share of Series J Preferred Stock is convertible at any time, at the election of the holder thereof, into the number of shares of Common Stock (the “Optional Conversion Shares”) equal to the quotient obtained by dividing (a) the Stated Value of such shares of Series J Preferred Stock by (b) the $0.95 conversion price, subject to certain adjustments.
	The Company is required to redeem all outstanding shares of Series J Preferred Stock for an amount in cash equal to the Liquidation Amount (as defined below) upon the Company’s receipt of a notice from the holders of Series H Preferred Stock that would require the Company to redeem the shares of Series H Preferred Stock pursuant to the Amended and Restated Certificate of Designation of Series H Convertible Preferred Stock (the “Series H Certificate of Designation”). The redemption of any shares of Series J Preferred Stock would be senior and prior to any redemption of Series H Preferred Stock or Series I Preferred Stock. Any holder of shares of Series J Preferred Stock may elect to have less than all or none of such holder’s shares of Series J Preferred Stock redeemed. At any time after the Company has redeemed any shares of Series H Preferred Stock each holder of shares of Series J Preferred Stock may elect to have all or a portion of such holder’s shares of Series J Preferred Stock redeemed by the Company for an amount in cash equal to the Liquidation Amount of such shares of Series J Preferred Stock.
	The “Liquidation Amount” of each share of Series J Preferred Stock is equal to the greater of (a) the fair market value of the Optional Conversion Shares and (b) an amount equal to the product obtained by multiplying (A) the Stated Value by (B) 2.0.
	Follow-On Series J Offering
	Between January 3, 2014 and August 28, 2014, the Company issued an aggregate of 25,475 units of its securities (the “Series J Securities”), at a purchase price of $1,000 per Series J Security for aggregate proceeds of $25.5 million (the “Follow-On Series J Offering”). Each Series J Security consists of (i) one share of Series J Preferred Stock and (ii) a warrant to purchase 2,650 shares of Common Stock, at an exercise price of $0.001 per share (the “Series J Warrants”). The Series J Securities were issued pursuant to separate Series J Securities Subscription Agreements between the Company and each of PCA Holdings, Holdings II, Riverwood Holdings, Cleantech Europe II (A) LP (“Cleantech A”) and Cleantech Europe II (B) LP (“Cleantech B” and together with Cleantech A, “Zouk”) and certain other accredited investors. The Company issued 6,000; 14,000; 2,860; 2,570 and 45 Series J Securities to Holdings II, PCA Holdings, Riverwood Holdings, Zouk and other accredited investors, respectively.
	The Follow-On Series J Offering was deemed to be a “Qualified Follow-On,” as such term was used and defined in the Amended and Restated Certificate of Designation of Series J Preferred Stock (the “Series J Certificate of Designation”) and the Preferred Stock Subscription Agreements (the “Existing Subscription Agreements”) by and between the Company and the Initial Series J Investors. As a result, and in accordance with the Existing Subscription Agreements, the Initial Series J Investors exchanged their Series J Preferred Stock for Series J Securities (the “Series J Exchange”). Accordingly, on January 3, 2014, each of LSGC Holdings II, PCA Holdings and Riverwood Holdings received Series J Warrants to purchase 36,191,050; 6,625,000 and 6,344,100 shares of Common Stock, respectively, in addition to the shares of Series J Preferred Stock purchased pursuant to the Existing Subscription Agreements. Pursuant to the terms of the Series J Certificate of Designation and the Existing Subscription Agreements, because Holdings II, PCA Holdings and Riverwood Holdings collectively held at least a majority of the issued and outstanding shares of Series J Preferred Stock and elected to participate in the Series J Exchange with respect to all of their previously purchased shares of Series J Preferred Stock, all of the Initial Series J Investors were required to participate in the Series J Exchange. As of September 30, 2014, the Company had issued an aggregate of 45,475 shares of Series J Preferred Stock and Series J Warrants to purchase an aggregate of 120,508,750 shares of Common Stock.
	In accordance with ASC 480, “Distinguishing Liabilities from Equity,” the shares of Series J Preferred Stock are recorded as mezzanine equity because such shares contain terms that allow the holder to redeem the shares for cash, and for which redemption is not solely within the control of the Company. In accordance with ASC 480-10-S99, the Company will recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the shares of Series J Preferred Stock to equal the redemption value at the end of each reporting period. The Series J Preferred Stock was recorded at redemption value on each date of issuance, which included a deemed dividend due to the redemption feature. As of September 30, 2014, Series J Preferred Stock redemption value included an aggregate deemed dividend of $66.6 million, which is reflected as an offset in additional paid-in capital.
	Series J Warrants
	Each Series J Warrant represents the right to purchase one share of Common Stock at an exercise price $0.001 and, if unexercised, expires on the fifth anniversary of their issuance date. The Series J Warrants were considered derivative financial instruments in accordance with ASC 815, “Derivatives and Hedging” due to the Company not having adequate shares available for issuance on the date that such warrants were issued. The Series J Warrants were recorded as a liability of $12.5 million based on an allocated portion of the cash proceeds of the Follow-On Series J Offering at issuance. Changes in fair value were measured and recorded at the end of each quarter using the Black Scholes valuation method. The change in fair value of the Series J Warrants was a decrease of $994,000 and an increase of $25.1 million for the period from March 31, 2014 to April 14, 2014 when the Series J Warrants were reclassified as equity instruments and the period from the date of issuance of the Series J Warrants to April 14, 2014, respectively, which was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss. The Series J Warrants were not exercisable until the Company effected the Charter Amendment. The Charter Amendment was effective April 14, 2014, at which point the Series J Warrants were reclassified as equity instruments.
	Pegasus Warrant
	The Pegasus Warrant was issued to Holdings II on September 11, 2013, in consideration for advisory services provided by Pegasus in connection with the Initial Series J Preferred Offering. The Pegasus Warrant represents the right to purchase 10,000,000 shares of Common Stock at a variable exercise price that will be determined on the date of exercise. The exercise price will be equal to the difference obtained by subtracting (a) the fair market value for each share of Common Stock on the day immediately preceding the date of exercise from (b) the quotient obtained by dividing (i) approximately 2.764% of the amount by which the total equity value of the Company exceeds approximately $570 million (as may be adjusted for subsequent capital raises) by (ii) the number of shares of Common Stock underlying the Pegasus Warrant; provided that for so long as the total equity value of the Company is less than or equal to approximately $570 million (as may be adjusted for subsequent capital raises) the Pegasus Warrant will not be exercisable. The Pegasus Warrant provides for certain anti-dilution adjustments and if unexercised, expires on May 25, 2022.
	The Pegasus Warrant is considered a derivative financial instrument in accordance with ASC 815-10-15, “Derivatives and Hedging” due to the variable nature of the warrant exercise price. The Pegasus Warrant was recorded as a liability at fair value using the Monte Carlo valuation method at issuance with changes in fair value measured and recorded at the end of each quarter. There was a decrease of $1.9 million and $965,000 in fair value of the Pegasus Warrant for the three and nine months ended September 30, 2014, which was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss. There was no change in fair value of the Pegasus Warrant for the period from September 11, 2013 (date of issuance) through September 30, 2013.

Series_H_and_Series_I_Redeemab

Series H and Series I Redeemable Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Series H and Series I Redeemable Convertible Preferred Stock	'
	NOTE 10. SERIES H AND SERIES I REDEEMABLE CONVERTIBLE PREFERRED STOCK
	Series H and I Preferred Stock
	On May 25, 2012, the Company entered into a preferred stock subscription agreement with Riverwood and certain other purchasers, pursuant to which the Company issued 60,705 shares of Series H Convertible Preferred Stock (the “Series H Preferred Stock”) and 6,364 shares of Series I Convertible Preferred Stock (the “Series I Preferred Stock” and together with the Series H Preferred Stock, the “Series H and I Preferred Shares”) at a price of $1,000 per Series H and I Preferred Share (the “Series H and I Preferred Offering”), for gross proceeds of $67.1 million. In conjunction with the Series H and I Preferred Offering, the Company entered into a Support Services Agreement (the “Riverwood Support Services Agreement”) with Riverwood Holdings and Riverwood Management. As compensation for Riverwood’s provision of certain financial and structural analysis, due diligence investigations, corporate strategy and other advice and negotiation assistance to the Company in connection with the Series H and I Preferred Offering, the Company issued warrants to Riverwood Management and certain of its affiliates (the “Riverwood Warrants”) representing the right to purchase an aggregate of 18,092,511 shares of Common Stock at a variable exercise price.
	On September 25, 2012, the Company entered into a separate preferred stock subscription agreement with each of (i) Portman Limited (“Portman”) and (ii) Zouk, pursuant to which the Company issued 49,000 shares of Series H Preferred Stock at a price of $1,000 per share of Series H Preferred Stock (the “September 2012 Preferred Offering”), for gross proceeds of $49.0 million. In conjunction with the September 2012 Preferred Offering, the Company also issued warrants to each of Portman, Cleantech A and Cleantech B to purchase 4,000,000; 3,406,041 and 593,959 shares of Common Stock, respectively (the “September 2012 Warrants”).
	The Series H and I Preferred Shares are entitled to dividends of the same type as any dividends or other distribution of any kind payable or to be made on outstanding shares of Common Stock, on an as converted basis. Each Series H and I Preferred Share is convertible at any time, at the election of the holder thereof, into the Optional Conversion Shares.
	In accordance with ASC 480, “Distinguishing Liabilities from Equity,” the Series H and I Preferred Shares are recorded as mezzanine equity because the Series H and I Preferred Shares contain terms that allow the holder to redeem the shares for cash at their option, and for which redemption is not solely within the control of the Company. In accordance with ASC 480-10-S99, the Company will recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the Series H and I Preferred Shares to equal the redemption value at the end of each reporting period. There was no change in the redemption value for the nine months ended September 30, 2014.
	Riverwood Warrants
	The Riverwood Warrants were issued to Riverwood Management on May 25, 2012 in consideration for services provided in connection with the Series H and I Preferred Offering. The Riverwood Warrants represent the right to purchase 18,092,511 shares of Common Stock at an exercise price to be determined on the date of exercise. The exercise price will be equal to the difference obtained by subtracting (a) the fair market value for each share of Common Stock on the day immediately preceding the date of exercise from (b) the quotient obtained by dividing (i) 5% of the amount by which the total equity value of the Company exceeds approximately $570 million (as may be adjusted for subsequent capital raises) by (ii) the number of shares of Common Stock underlying the Riverwood Warrants; provided that for so long as the total equity value of the Company is less than or equal to approximately $570 million (as may be adjusted for subsequent capital raises) the Riverwood Warrants will not be exercisable. The Riverwood Warrants provide for certain anti-dilution adjustments and if unexercised, expire on May 25, 2022.
	The Riverwood Warrants are considered derivative financial instruments in accordance with ASC 815-10-15, “Derivatives and Hedging” due to the variable nature of the exercise price. The Riverwood Warrants were recorded as a liability at fair value using the Monte Carlo valuation method at issuance with changes in fair value measured and recorded at the end of each quarter. The change in fair value of the Riverwood Warrants was a decrease of $3.4 million and $1.7 million for the three and nine months ended September 30, 2014, respectively, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss. The change in fair value of the Riverwood Warrants was an increase of $2.1 million and a decrease of $1.3 million for the three and nine months ended September 30, 2013, respectively, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss.
	September 2012 Warrants and September 2012 Commitment Agreement
	In connection with the issuance of the September 2012 Warrants, on September 25, 2012, the Company entered into a Commitment Agreement (the “September 2012 Commitment Agreement”) with Pegasus, pursuant to which the Company is obligated to buy from Pegasus IV or its affiliates shares of Common Stock equal to the number of shares, if any, for which the September 2012 Warrants are exercised, up to an aggregate number of shares of Common Stock equal to the aggregate number of shares of Common Stock underlying all of the September 2012 Warrants (the “Pegasus Commitment”). The purchase price for any shares of Common Stock purchased by the Company pursuant to the Pegasus Commitment will be equal to the consideration paid to the Company pursuant to the September 2012 Warrants. With respect to any September 2012 Warrants exercised on a cashless basis, the consideration to Pegasus IV in exchange for the number of shares of Common Stock issued to the exercising holder of September 2012 Warrants would be the reduction in the Pegasus Commitment equal to the reduction in the number of shares underlying the September 2012 Warrants.
	Subject to certain limitations, Pegasus IV has the right to cancel its obligations to the Company pursuant to the September 2012 Commitment Agreement with respect to all or a portion of the Pegasus Commitment then outstanding (a “Pegasus Call”). Upon the exercise of a Pegasus Call, the Company will have the obligation to purchase that number of September 2012 Warrants equal to the Pegasus Commitment subject to the Pegasus Call for an amount equal to the consideration paid by Pegasus IV pursuant to such Pegasus Call.
	The September 2012 Warrants are exercisable on or after the tenth business day following the third anniversary of the issuance date at an exercise price of $0.72 per share of Common Stock. If unexercised, the September 2012 Warrants expire upon the earlier of (i) a Change of Control of the Company (as defined in the Series H Certificate of Designation) prior to the three-year anniversary of their issuance date; (ii) the occurrence of any event that results in holders of shares of Series H Preferred Stock having a right to require the Company to redeem the shares of Series H Preferred Stock prior to the three-year anniversary of their issuance date; (iii) consummation of a qualified public offering (“QPO”) (as defined in the Series H Certificate of Designation) prior to the three-year anniversary of the issuance date or (iv) receipt by the Company of a Redemption Notice (as defined in the Subscription Agreements). The September 2012 Warrants also provide for certain anti-dilution adjustments.
	The September 2012 Warrants are considered derivative financial instruments in accordance with ASC 815-10-15, “Derivatives and Hedging” due to the cash settlement feature in the instrument. The September 2012 Warrants were recorded as a liability at fair value using the Monte Carlo valuation method at issuance with changes in fair value measured and recorded at the end of each quarter. The change in fair value of the September 2012 Warrants was a decrease of $960,000 and $367,000 for the three and nine months ended September 30, 2014, respectively, and was included in additional paid-in capital. The change in fair value of the September 2012 Warrants was an increase of $320,000 and $240,000 for the three and nine months ended September 30, 2013, respectively, and was included in additional paid-in capital.
	The Pegasus Commitment is classified as a financial instrument under ASC 480, “Distinguishing Liabilities from Equity” due to the Company’s obligation to purchase its own shares in the event the September 2012 Warrants are exercised by the holders. The Pegasus Commitment was recorded as an asset at fair value using the Monte Carlo valuation method at issuance with changes in fair value measured and recorded at the end of each quarter. The change in fair value of the Pegasus Commitment was a decrease of $960,000 and $367,000 for the three and nine months ended September 30, 2014, respectively, and was included in additional paid-in capital. The change in fair value of the Pegasus Commitment generally offsets the change in fair value of the September 2012 Warrants for the same period. The change in fair value of the Pegasus Commitment was an increase of $320,000 and $240,000 for the three and nine months ended September 30, 2013, respectively, and was included in additional paid-in capital.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	NOTE 11. STOCKHOLDERS’ EQUITY
	For the three and nine months ended September 30, 2014, the Company recorded expense of $221,000 and $412,000, respectively, related to restricted stock awards to the Company’s directors. For the three and nine months ended September 30, 2013, the Company recorded expense of $238,000 related to restricted stock awards and $0 and $20,000, respectively, related to stock options issued to the Company’s directors.
	On June 12, 2014, the Board approved the formation of a Scientific Advisory Board (the “SAB”) and issued restricted stock awards to each of the five members of the SAB as part of their compensation package. For the three and nine months ended September 30, 2014, the Company recorded expense of $26,000 and $31,000, respectively, related to restricted stock awards to the Company’s SAB.
	On January 2, 2013, Jeremy Cage was appointed Chief Executive Officer and the Company issued 500,000 shares of restricted stock to Mr. Cage as part of his compensation package. On March 22, 2013, the Company issued 192,308 shares of restricted stock to Brad Knight as part of his compensation package. For the three and nine months ended September 30, 2013, the Company recorded expense of $49,000 and $119,000, respectively, related to the restricted stock awards issued to Messrs. Cage and Knight.
	Warrants for the Purchase of Common Stock
	On January 13, 2011, the Company issued a warrant (the “THD Warrant”) to The Home Depot, Inc. (“The Home Depot”) pursuant to which The Home Depot may purchase up to 5.0 million shares of Common Stock at an exercise price of $2.00 per share, subject to certain vesting conditions. The THD Warrant was issued in connection with the Company’s Strategic Purchasing Agreement with The Home Depot, which it entered into on July 23, 2010 and pursuant to which it supplies The Home Depot with LED retrofit lamps and fixtures. The THD Warrant provided that 1.0 million shares of Common Stock would be eligible for vesting following each year ending December 31, 2011 through December 31, 2015, subject to The Home Depot having gross product orders from the Company, in dollar terms, that are at least 20% more than the gross product orders in the immediately preceding year. For the shares underlying the THD Warrant to be eligible for vesting following the years ending December 31, 2014 and 2015, The Home Depot would be required to extend the Strategic Purchasing Agreement for additional one-year periods beyond its initial term of three years. On August 12, 2013, the Company and The Home Depot entered into Amendment No. 1 to the Strategic Purchasing Agreement which, among other things, extended the term of the agreement for an additional three years. As of May 25, 2012, as a result of the Series H and I Preferred Offering, the exercise price of the THD Warrants adjusted, pursuant to the terms of such warrant, from $2.00 to $1.95 per share of Common Stock. The number of shares of Common Stock into which the THD Warrant was exercisable also adjusted, pursuant to the terms of the warrant, from 5,000,000 to 5,123,715 shares. As of August 28, 2014, as a result of Follow-On Series J Offering, the exercise price of the THD Warrant adjusted, pursuant to the terms of the warrant, from $1.95 to $1.37 per share of Common Stock. The number of shares of Common Stock into which the THD Warrant was exercisable also adjusted, pursuant to the terms of the warrant, from 5,123,715 to 7,321,347 shares. Each vested portion of the THD Warrant will expire on the third anniversary following the vesting of such portion.
	As of September 30, 2014, the following warrants for the purchase of Common Stock were outstanding:
	Warrant Holder	Reason for Issuance	Number of		Exercise		Expiration Date
			Common Shares		Price
	Investors in rights offering	Series D Warrants		825,634	$	3.83 to	March 3, 2022 through April 19,
					$	3.85	2022
	The Home Depot	Purchasing agreement		7,321,347	$	1.37	December 31, 2014 through
							2018
	RW LSG Management Holdings LLC	Riverwood Warrants		12,664,760		Variable	25-May-22
	Certain other investors	Riverwood Warrants		5,427,751		Variable	25-May-22
	Cleantech Europe II (A) LP	September 2012 Warrants		3,406,041	$	0.72	25-Sep-22
	Cleantech Europe II (B) LP	September 2012 Warrants		593,959	$	0.72	25-Sep-22
	Portman Limited	September 2012 Warrants		4,000,000	$	0.72	25-Sep-22
	Aquillian Investments LLC	Private Placement Series H		830,508	$	1.18	25-Sep-17
	Pegasus	Pegasus Warrant		10,000,000		Variable	25-May-22
	Investors in Series J Follow-On Offering	Series J Warrants		120,508,750	$	0.001	January 3, 2019 through
							August 27, 2019
	Medley	Medley Warrants		10,000,000	$	0.95	19-Feb-24
	Pegasus	Pegasus Guaranty Warrants		10,000,000	$	0.5	19-Feb-24
				185,578,750
	As of September 30, 2014, the warrants issued in connection with the Company’s previously redeemed Series D Convertible Preferred Stock, the warrants held by Aquillian Investments LLC, the Series J Warrants, the Medley Warrants and the Pegasus Guaranty Warrants and a portion of the THD Warrants were fully vested and exercisable. The September 2012 Warrants will become exercisable on October 9, 2015. Per the vesting terms discussed above, no shares issuable pursuant to the THD Warrant vested for the year ended December 31, 2013 and 1,494,269 shares issuable pursuant to the THD Warrant vested during both the years ended December 31, 2012 and 2011, for total warrants vested of 2,928,538, when the product purchases for these periods satisfied the prescribed vesting conditions, and 2,928,538 shares remain subject to vesting in accordance with similar product purchasing terms. Pursuant to the terms of the Riverwood Warrants and the Pegasus Warrant, these warrants were not exercisable as of September 30, 2014 because the aggregate fair market value of the Company’s outstanding shares of Common Stock (as determined in accordance with the terms of the Riverwood Warrants and the Pegasus Warrant) was less than the Company’s estimation of the required total equity value threshold of approximately $570 million (subject to adjustment in accordance with the terms of the Riverwood Warrants and the Pegasus Warrant).
	The fair value of the THD Warrant is determined using the Monte Carlo valuation method and will be adjusted at each reporting date until they have been earned for each year and these adjustments will be recorded as a reduction in the related revenue (sales incentive) from The Home Depot. As of September 30, 2014 and 2013, the Company determined that a portion of the THD Warrant was expected to vest during the period based on purchases made by The Home Depot during the nine months ended September 30, 2014 and 2013 and, accordingly, recorded a reduction in revenue of $38,000 and a reduction in revenue of $100,000 for the three and nine months ended September 30, 2014, respectively, and reductions in revenue of $9,000 and $23,000 for the three and nine months ended September 30, 2013, respectively. The change in fair value of the previously vested portion of the THD Warrant was an increase of $2,000 for the three and nine months ended September 30, 2014, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings (Loss) Per Share	'
	NOTE 12: EARNINGS (LOSS) PER SHARE
	Pursuant to that certain letter agreement, dated January 17, 2012 from the Company to LSGC Holdings (the “LSGC Letter Agreement”), the Company agreed to indemnify LSGC Holdings for, among other things, the cost of redeeming the Class C Interests in LSGC Holdings in the event that the Company issued preferred equity securities in excess of $80.0 million. Additionally, under the terms of the LSGC Letter Agreement, in the event that the Company would be required to indemnify LSGC Holdings under the LSGC Letter Agreement, LSGC Holdings agreed to surrender 3,750,000 shares of Common Stock to the Company less any shares of Common Stock previously distributed by LSGC Holdings to Continental Casualty Company. Following the consummation of the Series H and I Preferred Offering, the amount of preferred equity issued by the Company exceeded $80.0 million, and, as a result, LSGC Holdings was required to redeem 15,000,000 of its issued and outstanding senior preferred member interests held by Continental Casualty Company. Upon issuance of the LSGC Letter Agreement on January 17, 2012, the Company determined that two classes of Common Stock had been established for financial reporting purposes only, with Common Stock attributable to controlling stockholders representing shares beneficially owned and controlled by Pegasus and the Common Stock attributable to noncontrolling stockholders representing the minority interest stockholders. For the three and nine months ended September 30, 2014 and 2013, the Company computed net loss per share of noncontrolling stockholders and controlling stockholders of Common Stock using the two-class method. Net loss from operations is initially allocated based on the underlying common shares held by controlling and noncontrolling stockholders. The allocation of the net losses attributable to the Common Stock attributable to controlling stockholders is then reduced by the amount of the deemed dividend related to the Pegasus Guaranty Warrants, while the allocation of net losses attributable to the Common Stock attributable to noncontrolling stockholders is increased by the amount of the deemed dividend related to the Pegasus Guaranty Warrants (See Note 7 for further discussion).
	The following table sets forth the computation of basic and diluted net loss per share of Common Stock:
		For the Three Months Ended September 30,
		2014						2013
		Controlling			Noncontrolling			Controlling			Noncontrolling
		Stockholders			Stockholders			Stockholders			Stockholders
	Basic and diluted net income per share:
	Net loss attributable to common stock	$	(1,686,077	)	$	(416,499	)	$	(21,156,773	)	$	(4,346,354	)
	Deemed dividends related to the Series J Preferred Stock attributable to all shareholders		(9,571,504	)		(2,364,374	)		(17,910,579	)		(3,679,470	)
	Deemed dividends due to change in Series H and Series I Preferred Stock conversion price attributable to all shareholders		—			—			(11,982,712	)		(2,461,676	)
	Undistributed net loss	$	(11,257,581	)	$	(2,780,873	)	$	(51,050,064	)	$	(10,487,500	)
	Basic and diluted weighted average number of common shares outstanding		255,194,735			63,038,781			170,672,339			35,062,174
	Basic and diluted net loss per common share	$	(0.04	)	$	(0.04	)	$	(0.30	)	$	(0.30	)
		For the Nine Months Ended September 30,
		2014						2013
		Controlling			Noncontrolling			Controlling			Noncontrolling
		Stockholders			Stockholders			Stockholders			Stockholders
	Basic and diluted net income per share:
	Net loss attributable to common stock	$	(43,394,934	)	$	(10,430,121	)	$	(47,896,411	)	$	(9,822,624	)
	Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders		570,574			(570,574	)		—			—
	Deemed dividends related to the Series J Preferred Stock attributable to all shareholders		(34,077,591	)		(8,190,666	)		(17,915,855	)		(3,674,194	)
	Deemed dividends due to change in Series H and Series I Preferred Stock conversion price attributable to all shareholders		—			—			(11,986,242	)		(2,458,146	)
	Undistributed net loss	$	(76,901,951	)	$	(19,191,361	)	$	(77,798,508	)	$	(15,954,964	)
	Basic and diluted weighted average number of common shares outstanding		220,629,709			53,029,108			170,645,985			34,996,177
	Basic and diluted net loss per common share	$	(0.35	)	$	(0.36	)	$	(0.46	)	$	(0.46	)
	Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding for the applicable period. The Series J Warrants have an exercise price of $0.001 per share of Common Stock, and are included in the weighted average number of shares of Common Stock outstanding as there are no conditions that must be satisfied before such warrant may be exercised into the shares of Common Stock underlying such warrants. Diluted earnings per share is computed in the same manner as basic earnings per share except the number of shares is increased to assume exercise of potentially dilutive stock options, unvested restricted stock and contingently issuable shares using the treasury stock method and convertible preferred shares using the if-converted method, unless the effect of such increases would be anti-dilutive. The Company had 177.1 million and 174.4 million common stock equivalents for the three and nine months ended September 30, 2014, respectively, and 190.4 million and 186.8 million common stock equivalents for the three and nine months ended September 30, 2013, respectively, which were not included in the diluted net loss per common share as the common stock equivalents were anti-dilutive, as a result of being in a net loss position.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	NOTE 13: RELATED PARTY TRANSACTIONS
	On May 25, 2012, the Company entered into a Support Services Agreement (“Pegasus Support Services Agreement”) with Pegasus Capital, pursuant to which the Company agreed to pay Pegasus Capital $125,000 for each calendar quarter beginning on July 1, 2012, in exchange for certain support services during such periods. The Pegasus Support Services Agreement expires upon the earlier of: (i) June 30, 2017; (ii) a Change of Control (as defined therein) or (iii) a QPO. During the first 30 days of any calendar quarter, the Company has the right to terminate the Pegasus Support Services Agreement, effective immediately upon written notice to Pegasus Capital. Pegasus Capital is an affiliate of Pegasus IV and LSGC Holdings, which are the Company’s largest stockholders and beneficially owned approximately 87.8% of the Company’s Common Stock as of September 30, 2014.
	On May 25, 2012, the Company entered into the Riverwood Support Services Agreement with Riverwood Holdings, pursuant to which the Company agreed to pay Riverwood Holdings $20,000 for the period from May 25, 2012 through June 30, 2012 and thereafter $50,000 for each calendar quarter beginning on July 1, 2012, in exchange for certain support services during such periods. The Riverwood Support Services Agreement expires upon the earlier of: (i) May 25, 2022, (ii) such date that Riverwood Management and/or its affiliates directly or indirectly beneficially own less than 37.5% of the shares of Series H Preferred Stock purchased pursuant to the Series H and I Preferred Offering, on an as-converted basis (together with any shares of Common Stock issued upon conversion thereof); (iii) such date that the Company and Riverwood may mutually agree in writing (iv) a Change of Control (as defined in the Riverwood Warrant) or (v) a QPO. In addition, the Company has brought in several employees of Riverwood to provide consulting services. During the three and nine months ended September 30, 2014, the Company incurred $2,000, and $872,000, respectively, of consulting fees for services provided by Riverwood, included in selling, distribution and administrative expense. During the three and nine months ended September 30, 2013, the Company incurred $656,000, and $1.7 million, respectively, of consulting fees for services provided by Riverwood, included in selling, distribution and administrative expense.
	In connection with the September 2012 Preferred Offering, the Company entered into a Support Services Agreement (the “Zouk Support Services Agreement”) with Zouk, pursuant to which the Company agreed to pay Zouk $100,000 each calendar quarter beginning with the quarter ended September 30, 2012, in exchange for certain support services during such periods. The Zouk Support Services Agreement expires upon the earlier of: (i) September 25, 2022; (ii) such date that Zouk and/or its affiliates directly or indirectly beneficially own less than 37.5% of the shares of Series H Preferred Stock purchased pursuant to the September 2012 Preferred Offering, on an as-converted basis; (iii) such date that the Company and Zouk may mutually agree in writing; (iv) a Change of Control (as defined in the September 2012 Warrants) and (v) a QPO.
	On September 25, 2012, and in connection with the September 2012 Preferred Offering each of Pegasus Capital, Riverwood Holdings, Portman and Zouk entered into a Fee Waiver Letter Agreement, pursuant to which the parties agreed to suspend payment of the fees payable in connection with their respective support services or other agreements between the Company and such parties until revoked by their unanimous written consent.
	On February 19, 2014, the Company entered into the Pegasus Guaranty and, as consideration for the Pegasus Guaranty, the Company issued the Pegasus Guaranty Warrants. The Pegasus Guaranty Warrants were valued at $3.3 million as of February 19, 2014, which was partially offset by the $2.8 million fair value of the Pegasus Guaranty, with the remaining value of $571,000 accounted for as a deemed dividend to the Company’s controlling stockholders. For the three and nine months ended September 30, 2014, the Company recorded $138,000 and $338,000, respectively, of non-cash related party interest expense related to the amortization of the Pegasus Guaranty.
	On January 3, 2014, the Company issued 2,860 Series J Securities to Riverwood Holdings for aggregate proceeds of $2.9 million. On January 9, 2014, the Company issued 2,570 Series J Securities to Zouk for aggregate proceeds of $2.6 million.
	On January 3, 2014, the Company issued 2,000 and 6,000 Series J Securities to PCA Holdings and Holdings II, respectively, for aggregate proceeds of $8.0 million. On January 9, 2014, the Company issued 4,000 Series J Securities to PCA Holdings for aggregate proceeds of $4.0 million. From August 14 through August 28, 2014, the Company issued an aggregate of 8,000 Series J Securities to PCA Holdings for aggregate proceeds of $8.0 million.
	During both the three and nine months ended September 30, 2014, the Company incurred $9,000 in consulting fees for services provided by T&M Protection Resources. T&M Protection Resources is a security company affiliated with Pegasus Capital. During the three and nine months ended September 30, 2013, the Company incurred consulting fees of $0 and $15,000, respectively, for services provided by T&M Protection Resources, primarily for the facility in Monterrey, Mexico, which were included in selling, distribution and administrative expense.

Concentrations_of_Credit_Risk

Concentrations of Credit Risk	9 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentrations of Credit Risk	'
	NOTE 14. CONCENTRATIONS OF CREDIT RISK
	For the three and nine months ended September 30, 2014, the Company had one customer whose revenue represented 82% and 78% of total revenue, respectively. For the three and nine months ended September 30, 2013, the Company had one customer whose revenue represented 56% and 52% of total revenue, respectively.
	As of September 30, 2014 and December 31, 2013, the Company had one customer whose accounts receivable balance represented 77% and 55% of accounts receivable, net of allowances, respectively.

Restructuring_Expense

Restructuring Expense	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring Expense	'
	NOTE 15. RESTRUCTURING EXPENSE
	The following table summarizes our restructuring expense and related charges for the following periods ended September 30:
			For the Nine Months Ended September 30,
			2014			2013
	Broad based reduction of facilities and personnel (1)		$	2,558,072		$	—
	Mexico Closing (2)			—			130,557
	Organization Optimization Initiative (3)			114,278			53,550
	Total		$	2,672,350		$	184,107
	-1	These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes moving the majority of the Company’s manufacturing to its contract manufacturers in Asia, related workforce reductions in Satellite Beach, Florida and cost reductions in our foreign subsidiaries. In addition to the charges noted above, the Company expects to incur approximately $446,000 in additional expenses throughout this cost reduction plan, primarily related to additional headcount reductions. These additional costs are expected to be incurred by the end of 2014.
	-2	On September 24, 2012, the Company’s Board of Directors committed to the closing of our manufacturing facility in Mexico, which was substantially complete as of December 31, 2013. During the nine months ended September 30, 2013, expense incurred related to termination of the lease on the Mexico manufacturing facility.
	-3	In September 2011, the Company began implementing a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. This restructuring plan included a reduction in full time headcount in the United States, which was completed in October 2011. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount in Mexico resulting from the Company’s continued shift of its manufacturing and production processes to the Company’s contract manufacturer in Mexico, the replacement of 10 members of management in the United States following the completion of the Series H and I Preferred Offering in May 2012 and the closing of the Company’s offices in the United Kingdom and Australia. For the nine months ended September 30, 2014, these expenses relate to the final liquidation of the Australian entity.
	As of September 30, 2014, the accrued liability associated with the restructuring and other related charges consisted of the following:
			Workforce			Other			Total
			Reduction			Exit Costs
	Accrued liability as of December 31, 2013		$	699,832		$	276,956		$	976,788
	Charges			2,026,786			117,960			2,144,746
	Reversals			—			(94,214	)		(94,214	)
	Payments			(1,511,513	)		(193,376	)		(1,704,889	)
	Accrued liability as of September 30, 2014		$	1,215,105		$	107,326		$	1,322,431
	The remaining accrual as of September 30, 2014, of $1.3 million is expected to be paid during the fourth quarter of 2014 and during the year ending December 31, 2015.
	The restructuring and other related charges are included in the line item restructuring expense in the condensed consolidated statement of operations and comprehensive loss.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	NOTE 16. COMMITMENTS AND CONTINGENCIES
	Legal Proceedings
	The Company is subject to the possibility of loss contingencies arising in its business. Such contingencies are accounted for in accordance with ASC Topic 450, “Contingencies.” In determining loss contingencies, the Company considers the possibility of a loss and the ability to reasonably estimate the amount of such loss or liability. An estimated loss is recorded when it is considered probable that a liability has been incurred and when the amount of loss can be reasonably estimated. In the ordinary course of business, the Company is routinely a defendant in or party to various pending and threatened legal claims and proceedings. The Company believes that any liability resulting from these various claims, except as noted below, will not have a material adverse effect on its results of operations or financial condition; however, it is possible that extraordinary or unexpected legal fees could adversely impact the Company’s financial results during a particular period. During its ordinary course of business, the Company enters into obligations to defend, indemnify and/or hold harmless various customers, officers, directors, employees, and other third parties. These contractual obligations could give rise to additional litigation costs and involvement in court proceedings.
	On June 22, 2012, Geveran Investments Limited (“Geveran”), a stockholder of the Company, which had purchased common shares for $25.0 million on May 10, 2011, filed a lawsuit against the Company and several other parties in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida styled Geveran Investments Limited v. Lighting Science Group Corp., et al., Case No. 12-17738 (07) (the “Geveran Suit”). On October 30, 2012, the court entered an order transferring the lawsuit to the Ninth Judicial Circuit in and for Orange County, Florida. In its Second Amended Complaint, Geveran sought rescissionary damages in the amount of $25.0 million, as well as recovery of attorneys’ fees and court costs, jointly and severally against the Company, Pegasus Capital, a former director and former interim chief executive officer of the Company, the Company’s former chief financial officer, J.P. Morgan Securities LLC (“J.P. Morgan”) and two of its employees, for alleged violation of the Florida Securities and Investor Protection Act (“FSIPA”). Geveran alternatively sought unspecified money damages and punitive damages, as well as recovery of court costs, for alleged common law claims for fraud, negligent misrepresentation, aiding and abetting fraud and conspiracy against these defendants and other Pegasus entities.
	On August 28, 2014, the Court issued an order, without findings of fact, granting Geveran’s Motion for Partial Summary Judgment under its FSIPA cause of action against the Company and the other defendants. The parties subsequently entered into a court approved stipulation to voluntarily dismiss all unresolved claims without prejudice and to reinstate those claims in the event that an appellate court reverses the Court’s ruling and remands for further proceedings. Pursuant to such stipulation and extensions granted by the Court, Geveran is to file a motion to request the Court to assess reasonable attorneys’ fees, court costs and pre-judgment interest on or before November 25, 2014. The stipulation also provides that following a resolution of this motion, the Court would enter a judgment for $25.0 million plus attorneys’ fees, court costs and pre-judgment interest after which time the defendants would file an appeal. For a period of 30 days following entry of the judgment, the enforcement of the judgment would be temporarily stayed pursuant to the stipulation in order that the defendants may post an appeal bond.
	The Company believes that the Court’s partial summary judgment ruling in favor of Geveran was erroneous and intends to continue to vigorously defend this lawsuit on appeal with the Florida Fifth District Court of Appeals. The amount of possible loss, if any, cannot be reasonably estimated at this time. The ultimate outcome, if unfavorable, could have a material adverse effect on the Company.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. The Company’s actual results could differ from these estimates.
Restricted Cash	'
	Restricted Cash
	As of September 30, 2014, as required by the Company’s five-year term loan (the “Medley Term Loan”) with Medley Capital Corporation (“Medley”), the Company was required to maintain a minimum restricted cash balance of $3.0 million to collateralize the Medley Term Loan. As of December 31, 2013, as required by the Company’s asset-based revolving credit facility (as amended, the “Wells Fargo ABL”) with Wells Fargo Bank N.A. (“Wells Fargo”), the Company was required to maintain a minimum qualified cash balance of $5.0 million as a compensating balance against the Wells Fargo ABL. Changes in the restricted cash balance are reflected as a financing activity in the consolidated statement of cash flows.
Accounts Receivable	'
	Accounts Receivable
	The Company records accounts receivable at the invoiced amount when its products are shipped to customers or when specific milestone billing requirements are completed. The Company’s accounts receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, age of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based on age or customer circumstances, that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of September 30, 2014 and December 31, 2013, the Company’s accounts receivable were reflected net of an allowance for doubtful accounts of $331,000 and $475,000, respectively.
	As of September 30, 2014, $9.2 million of eligible accounts receivable were pledged as collateral for the three year asset based revolving credit facility (the “FCC ABL”) entered into on April 25, 2014 with FCC, LLC d/b/a First Capital (“First Capital”). As of December 31, 2013, $6.8 million of eligible accounts receivable were pledged as collateral for the Wells Fargo ABL.
Revenue Recognition	'
	Revenue Recognition
	The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once those terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). ASU 2014-09 seeks to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2014-09, but the standard is not expected to have a significant effect on its consolidated financial statements.
Product Warranties	'
	Product Warranties
	The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products. Such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The warranty provision is included in accrued expenses on the condensed consolidated balance sheet. Changes in the warranty provision for the nine months ended September 30, 2014 were as follows:
	Warranty provision as of December 31, 2013	$	3,231,991
	Additions to provision		2,404,970
	Less warranty costs		(2,481,116	)
	Warranty provision as of September 30, 2014	$	3,155,845
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and note payable are carried at amounts that approximate their fair value due to the short-term maturity of these instruments and/or variable, market driven interest rates.
	The Riverwood Warrants, September 2012 Warrants and the Pegasus Commitment (each as defined in Note 10 below), the Pegasus Warrant and Series J Warrants, (each as defined in Note 9 below) and the Medley Warrants and Pegasus Guaranty Warrants (each as defined in Note 7 below) were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period. Once a portion of the THD Warrant (as defined in Note 11 below) vests it is recorded at its fair value at the end of each subsequent reporting period.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Warranty Provision	'
	Changes in the warranty provision for the nine months ended September 30, 2014 were as follows:
	Warranty provision as of December 31, 2013	$	3,231,991
	Additions to provision		2,404,970
	Less warranty costs		(2,481,116	)
	Warranty provision as of September 30, 2014	$	3,155,845

Detail_of_Certain_Balance_Shee1

Detail of Certain Balance Sheet Accounts (Tables)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule of Inventory	'
	Inventories consisted of the following as of the dates indicated:
		September 30, 2014			December 31, 2013
	Raw materials and components	$	1,631,251		$	6,868,139
	Work-in-process		—			1,599,089
	Finished goods		19,984,833			10,593,891
	Total inventory, net	$	21,616,084		$	19,061,119
Schedule of Property and Equipment, Net	'
	Property and equipment, net consisted of the following as of the dates indicated:
		September 30, 2014			December 31, 2013
	Leasehold improvements	$	474,192		$	1,486,628
	Office furniture and equipment		483,139			1,141,314
	Computer hardware and software		8,118,864			8,802,484
	Tooling, production and test equipment		4,446,313			16,141,358
	Trailers		45,996			—
	Construction-in-process		133,396			325,252
	Total property and equipment		13,701,900			27,897,036
	Accumulated depreciation		(10,484,199	)		(21,398,431	)
	Total property and equipment, net	$	3,217,701		$	6,498,605

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets	'
	The Company’s intangible assets as of September 30, 2014 and December 31, 2013 are detailed below:
		Cost, Less		Accumulated			Net Book		Estimated
		Impairment		Amortization			Value		Remaining
		Charges							Useful Life
	September 30, 2014:
	Technology and intellectual property	$	2,688,121	$	(205,833	)	$	2,482,288		2.7 to 20.0 years
	December 31, 2013:
	Technology and intellectual property	$	2,011,654	$	(161,243	)	$	1,850,411		3.2 to 20.0 years

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Company's Financial Assets and Liabilities that were Accounted for at Fair Value on a Recurring Basis	'
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2014, according to the valuation techniques the Company used to determine their fair values:
		Fair Value Measurement as of September 30, 2014
		Quoted Price in			Significant Other			Significant
		Active Markets for			Observable Inputs			Unobservable Inputs
		Identical Assets
		Level 1			Level 2			Level 3
	Assets (Recurring):
	Pegasus Commitment	$	—		$	—		$	1,040,000
	Liabilities (Recurring):
	Riverwood Warrants	$	—		$	—		$	3,256,653
	September 2012 Warrants		—			—			1,040,000
	Pegasus Warrant		—			—			1,800,000
	THD Warrant		—			—			114,443
	Medley Warrants		—			—			1,323,312
	Pegasus Guaranty Warrants		—			—			1,435,381
		$	—		$	—		$	8,969,789
Reconciliation of the Beginning and Ending Balances for Assets and Liabilities that were Accounted for at Fair Value on a Recurring Basis	'
	The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the nine months ended September 30, 2014:
		Balance			Realized and unrealized			Purchases, sales,			Transfers in			Balance
		December 31, 2013			gains (losses) included			issuances and			or out of			September 30, 2014
					in net loss			settlements			Level 3
	Pegasus Commitment	$	1,407,335		$	(367,335	)	$	—		$	—		$	1,040,000
	Riverwood Warrants		(5,002,664	)		1,746,011			—			—			(3,256,653	)
	September 2012 Warrants		(1,407,335	)		367,335			—			—			(1,040,000	)
	Pegasus Warrant		(2,765,047	)		965,047			—			—			(1,800,000	)
	THD Warrant		—			(39,867	)		—			(74,576	)		(114,443	)
	Series J Warrants		—			(25,140,561	)		(12,505,739	)		37,646,300			—
	Medley Warrants		—			1,847,049			(3,170,361	)		—			(1,323,312	)
	Pegasus Guaranty Warrants		—			1,901,193			(3,336,574	)		—			(1,435,381	)
	Total	$	(7,767,711	)	$	(18,721,128	)	$	(19,012,674	)	$	37,571,724		$	(7,929,789	)
	The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the nine months ended September 30, 2013:
		Balance			Realized and unrealized			Purchases, sales,			Transfers in			Balance
		December 31, 2012			gains (losses) included			issuances and			or out of			September 30, 2013
					in net loss			settlements			Level 3
	Pegasus Commitment	$	1,360,000		$	240,000		$	—		$	—		$	1,600,000
	Riverwood Warrants		(7,960,705	)		1,320,753			—			—			(6,639,952	)
	September 2012 Warrants		(1,360,000	)		(240,000	)		—			—			(1,600,000	)
	Pegasus Warrant		—			—			(3,700,000	)		—			(3,700,000	)
	Total	$	(7,960,705	)	$	1,320,753		$	(3,700,000	)	$	—		$	(10,339,952	)

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Schedule of Warrants for Purchase of Common Stock	'
	As of September 30, 2014, the following warrants for the purchase of Common Stock were outstanding:
	Warrant Holder	Reason for Issuance	Number of		Exercise		Expiration Date
			Common Shares		Price
	Investors in rights offering	Series D Warrants		825,634	$	3.83 to	March 3, 2022 through April 19,
					$	3.85	2022
	The Home Depot	Purchasing agreement		7,321,347	$	1.37	December 31, 2014 through
							2018
	RW LSG Management Holdings LLC	Riverwood Warrants		12,664,760		Variable	25-May-22
	Certain other investors	Riverwood Warrants		5,427,751		Variable	25-May-22
	Cleantech Europe II (A) LP	September 2012 Warrants		3,406,041	$	0.72	25-Sep-22
	Cleantech Europe II (B) LP	September 2012 Warrants		593,959	$	0.72	25-Sep-22
	Portman Limited	September 2012 Warrants		4,000,000	$	0.72	25-Sep-22
	Aquillian Investments LLC	Private Placement Series H		830,508	$	1.18	25-Sep-17
	Pegasus	Pegasus Warrant		10,000,000		Variable	25-May-22
	Investors in Series J Follow-On Offering	Series J Warrants		120,508,750	$	0.001	January 3, 2019 through
							August 27, 2019
	Medley	Medley Warrants		10,000,000	$	0.95	19-Feb-24
	Pegasus	Pegasus Guaranty Warrants		10,000,000	$	0.5	19-Feb-24
				185,578,750

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Net Loss Per Share of Common Stock	'
	The following table sets forth the computation of basic and diluted net loss per share of Common Stock:
		For the Three Months Ended September 30,
		2014						2013
		Controlling			Noncontrolling			Controlling			Noncontrolling
		Stockholders			Stockholders			Stockholders			Stockholders
	Basic and diluted net income per share:
	Net loss attributable to common stock	$	(1,686,077	)	$	(416,499	)	$	(21,156,773	)	$	(4,346,354	)
	Deemed dividends related to the Series J Preferred Stock attributable to all shareholders		(9,571,504	)		(2,364,374	)		(17,910,579	)		(3,679,470	)
	Deemed dividends due to change in Series H and Series I Preferred Stock conversion price attributable to all shareholders		—			—			(11,982,712	)		(2,461,676	)
	Undistributed net loss	$	(11,257,581	)	$	(2,780,873	)	$	(51,050,064	)	$	(10,487,500	)
	Basic and diluted weighted average number of common shares outstanding		255,194,735			63,038,781			170,672,339			35,062,174
	Basic and diluted net loss per common share	$	(0.04	)	$	(0.04	)	$	(0.30	)	$	(0.30	)
		For the Nine Months Ended September 30,
		2014						2013
		Controlling			Noncontrolling			Controlling			Noncontrolling
		Stockholders			Stockholders			Stockholders			Stockholders
	Basic and diluted net income per share:
	Net loss attributable to common stock	$	(43,394,934	)	$	(10,430,121	)	$	(47,896,411	)	$	(9,822,624	)
	Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders		570,574			(570,574	)		—			—
	Deemed dividends related to the Series J Preferred Stock attributable to all shareholders		(34,077,591	)		(8,190,666	)		(17,915,855	)		(3,674,194	)
	Deemed dividends due to change in Series H and Series I Preferred Stock conversion price attributable to all shareholders		—			—			(11,986,242	)		(2,458,146	)
	Undistributed net loss	$	(76,901,951	)	$	(19,191,361	)	$	(77,798,508	)	$	(15,954,964	)
	Basic and diluted weighted average number of common shares outstanding		220,629,709			53,029,108			170,645,985			34,996,177
	Basic and diluted net loss per common share	$	(0.35	)	$	(0.36	)	$	(0.46	)	$	(0.46	)

Restructuring_Expense_Tables

Restructuring Expense (Tables)	9 Months Ended
	Sep. 30, 2014
Accrued Liability Associated with Restructuring Charges	'
	The following table summarizes our restructuring expense and related charges for the following periods ended September 30:
			For the Nine Months Ended September 30,
			2014			2013
	Broad based reduction of facilities and personnel (1)		$	2,558,072		$	—
	Mexico Closing (2)			—			130,557
	Organization Optimization Initiative (3)			114,278			53,550
	Total		$	2,672,350		$	184,107
	-1	These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes moving the majority of the Company’s manufacturing to its contract manufacturers in Asia, related workforce reductions in Satellite Beach, Florida and cost reductions in our foreign subsidiaries. In addition to the charges noted above, the Company expects to incur approximately $446,000 in additional expenses throughout this cost reduction plan, primarily related to additional headcount reductions. These additional costs are expected to be incurred by the end of 2014.
	-2	On September 24, 2012, the Company’s Board of Directors committed to the closing of our manufacturing facility in Mexico, which was substantially complete as of December 31, 2013. During the nine months ended September 30, 2013, expense incurred related to termination of the lease on the Mexico manufacturing facility.
	-3	In September 2011, the Company began implementing a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. This restructuring plan included a reduction in full time headcount in the United States, which was completed in October 2011. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount in Mexico resulting from the Company’s continued shift of its manufacturing and production processes to the Company’s contract manufacturer in Mexico, the replacement of 10 members of management in the United States following the completion of the Series H and I Preferred Offering in May 2012 and the closing of the Company’s offices in the United Kingdom and Australia. For the nine months ended September 30, 2014, these expenses relate to the final liquidation of the Australian entity.
Accrued Liabilities [Member]	'
Accrued Liability Associated with Restructuring Charges	'
	As of September 30, 2014, the accrued liability associated with the restructuring and other related charges consisted of the following:
			Workforce			Other			Total
			Reduction			Exit Costs
	Accrued liability as of December 31, 2013		$	699,832		$	276,956		$	976,788
	Charges			2,026,786			117,960			2,144,746
	Reversals			—			(94,214	)		(94,214	)
	Payments			(1,511,513	)		(193,376	)		(1,704,889	)
	Accrued liability as of September 30, 2014		$	1,215,105		$	107,326		$	1,322,431

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	9 Months Ended		0 Months Ended				9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Feb. 19, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Sep. 30, 2014
			Medley Term Loan [Member]	Medley Term Loan [Member]	Wells Fargo ABL [Member]	Wells Fargo ABL [Member]	First Capital [Member]
				Minimum [Member]		Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'
Minimum required restricted cash balance	$3,000,000	$5,000,000	'	$3,000,000	'	$5,000,000	'
Allowance for doubtful accounts receivable	331,000	475,000	'	'	'	'	'
Credit facility expiration period	'	'	'5 years	'	'	'	'3 years
Eligible accounts receivable pledged as collateral for assets based credit facility	'	'	'	'	$6,800,000	'	$9,200,000
Period of warranty on products	'5 years	'	'	'	'	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Warranty Provision (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Product Warranties Disclosures [Abstract]	'
Warranty provision, Beginning Balance	$3,231,991
Additions to provision	2,404,970
Less warranty costs	-2,481,116
Warranty provision, Ending Balance	$3,155,845

Liquidity_and_Capital_Resource1

Liquidity and Capital Resources - Additional Information (Detail) (USD $)

9 Months Ended

0 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Nov. 14, 2014

Feb. 19, 2014

Sep. 30, 2014

Feb. 19, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Third Party Investor [Member]

Medley Term Loan [Member]

Medley Term Loan [Member]

Medley Term Loan [Member]

Medley Term Loan [Member]

First Capital [Member]

First Capital [Member]

First Capital [Member]

First Capital [Member]

First Capital [Member]

Subsequent Event [Member]

Minimum [Member]

Accounts Receivable [Member]

Certain Eligible Inventories [Member]

Net Orderly Liquidation Value, Eligible Inventories [Member]

Certain Other Eligible Inventories [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Liquidity And Capital Resources [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated deficit

($788,558,955)

'

($734,733,900)

'

'

'

'

'

'

'

'

'

'

'

Stockholders' deficit

-463,500,385

'

-410,849,963

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

Credit facility borrowing amount

50,000,000

'

'

'

'

'

30,500,000

30,500,000

'

22,500,000

'

'

'

'

Credit facility maturity period

'

'

'

'

'

'5 years

'

'

'

'3 years

'

'

'

'

Amount outstanding under credit facility

'

'

'

'

'

'

'

'

'

12,200,000

'

'

'

'

Remaining borrowing capacity

'

'

'

'

'

'

'

'

'

6,700,000

'

'

'

'

Cash and cash equivalents

1,238,030

10,292,524

11,195,412

15,834,077

'

'

'

'

'

'

'

'

'

'

Restricted cash under asset-based revolving credit facility

3,000,000

'

5,000,000

'

'

'

'

'

3,000,000

'

'

'

'

'

Concentration risk, percentage

'

'

'

'

'

'

'

'

'

'

85.00%

65.00%

85.00%

65.00%

Borrowing base, maximum amount added to certain eligible accounts

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

Borrowing base, maximum amount added to other inventories

'

'

'

'

'

'

'

'

'

4,500,000

'

'

'

'

Description of Line of Credit with Medley Delayed Draw Loan

'The FCC ABL provides the Company with a maximum borrowing capacity of $22.5 million, which capacity is equal to (i) the sum of (A) 85% of the Company's eligible accounts receivable and (B) the lesser of (a) $10 million and (b) the sum of (x) the lesser of (1) 65% of the dollar value of certain eligible inventory and (2) 85% of the net orderly liquidation value of such eligible inventory, (y) 65% of certain other inventory and (z) the lesser of (1) $4.5 million and (2) the lesser of 65% of the dollar value, or 85% of the net orderly liquidation value, of eligible inventory that is in-transit, minus (ii) the sum of reserves established by First Capital and the aggregate amount of the Company's outstanding letter of credit obligations (collectively, the "Borrowing Base"). The Company is at all times required to maintain (i) a Borrowing Base that exceeds the amount of its outstanding borrowings under the FCC ABL and (ii) $3.0 million in restricted cash pursuant to the Medley Loan Agreement. The Company is required to comply with certain specified EBITDA requirements, maintain a specified lamp sourcing percentage and comply with maximum capital expenditure limits.

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum payment obligation of the Company in the event of a redemption of all the Series H, I and J Preferred Stock

442,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate borrowings outstanding under each of these loan facilities

39,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of Series J Redeemable Convertible Preferred Securities

$25,475,000

$17,394,000

'

'

$10,000,000

'

'

'

'

'

'

'

'

'

Detail_of_Certain_Balance_Shee2

Detail of Certain Balance Sheet Accounts - Schedule of Inventory (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]	'	'
Raw materials and components	$1,631,251	$6,868,139
Work-in-process	'	1,599,089
Finished goods	19,984,833	10,593,891
Total inventory, net	$21,616,084	$19,061,119

Detail_of_Certain_Balance_Shee3

Detail of Certain Balance Sheet Accounts - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'	'	'	'
Consigned inventory	$932,000	'	$932,000	'	$693,000
Inventory allowances	9,600,000	'	9,600,000	'	24,100,000
Depreciation related to property and equipment	$599,000	$2,600,000	$2,600,000	$6,900,000	'

Detail_of_Certain_Balance_Shee4

Detail of Certain Balance Sheet Accounts - Schedule of Property and Equipment, Net (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	$13,701,900	$27,897,036
Accumulated depreciation	-10,484,199	-21,398,431
Total property and equipment, net	3,217,701	6,498,605
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	474,192	1,486,628
Office Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	483,139	1,141,314
Computer Hardware and Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	8,118,864	8,802,484
Tooling, Production and Test Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	4,446,313	16,141,358
Trailers [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	45,996	'
Construction-in-process [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	$133,396	$325,252

Intangible_Assets_Schedule_of_

Intangible Assets - Schedule of Intangible Assets (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Indefinite-lived Intangible Assets [Line Items]	'	'
Net Book Value	2,482,288	1,850,411
Technology and Intellectual Property [Member]	'	'
Indefinite-lived Intangible Assets [Line Items]	'	'
Cost, Less Impairment Charges	2,688,121	2,011,654
Accumulated Amortization	-205,833	-161,243
Net Book Value	2,482,288	1,850,411
Minimum [Member] | Technology and Intellectual Property [Member]	'	'
Indefinite-lived Intangible Assets [Line Items]	'	'
Estimated Remaining Useful Life	'2 years 8 months 12 days	'3 years 2 months 12 days
Maximum [Member] | Technology and Intellectual Property [Member]	'	'
Indefinite-lived Intangible Assets [Line Items]	'	'
Estimated Remaining Useful Life	'20 years	'20 years

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization expense of intangible assets	$17,000	$12,000	$46,000	$27,000

Debt_Issuance_Costs_Additional

Debt Issuance Costs - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Debt Instrument [Line Items]	'	'	'	'	'
Debt issuance costs net	$3,516,719	'	$3,516,719	'	$113,283
Debt issuance costs at fair value	'	'	6,000,000	'	'
Current portion of the debt issuance costs	1,300,000	'	1,300,000	'	'
Amortized debt issuance costs	312,000	117,000	1,299,931	394,329	'
Pegasus Guaranty [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Debt issuance costs at fair value	'	'	$2,800,000	'	'

Lines_of_Credit_and_Note_Payab1

Lines of Credit and Note Payable - Additional Information (Detail) (USD $)

9 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

7 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

9 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

3 Months Ended

7 Months Ended

9 Months Ended

3 Months Ended

7 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Feb. 19, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Feb. 19, 2014

Feb. 19, 2014

Sep. 21, 2011

Sep. 19, 2014

Sep. 30, 2014

Sep. 19, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Feb. 19, 2014

Sep. 30, 2014

Feb. 19, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Feb. 19, 2014

Sep. 30, 2014

Medley Capital Corporation [Member]

Pegasus Guaranty and Pegasus Guaranty Warrants [Member]

Pegasus Guaranty and Pegasus Guaranty Warrants [Member]

Pegasus Guaranty and Pegasus Guaranty Warrants [Member]

Pegasus Guaranty and Pegasus Guaranty Warrants [Member]

Pegasus Guaranty and Pegasus Guaranty Warrants [Member]

Pegasus Guaranty and Pegasus Guaranty Warrants [Member]

Ares Capital [Member]

First Capital [Member]

First Capital [Member]

First Capital [Member]

First Capital [Member]

First Capital [Member]

First Capital [Member]

First Capital [Member]

Medley Term Loan [Member]

Medley Term Loan [Member]

Medley Term Loan [Member]

Medley Term Loan [Member]

Medley Term Loan [Member]

Medley Term Loan [Member]

Medley Warrants [Member]

Medley Warrants [Member]

Medley Warrants [Member]

Medley Warrants [Member]

Medley Warrants [Member]

Implied Interest Rate Analysis [Member]

Accounts Receivable [Member]

Certain Eligible Inventories [Member]

Net Orderly Liquidation Value, Eligible Inventories [Member]

Certain Other Eligible Inventories [Member]

Interest Expense [Member]

Interest Expense [Member]

Commitment Fees [Member]

Commitment Fees [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility borrowing amount

$50,000,000

'

'

$22,500,000

'

'

'

'

'

'

'

'

$22,500,000

'

'

'

'

'

'

$30,500,000

$30,500,000

'

'

'

'

'

'

'

'

Concentration risk, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

65.00%

85.00%

65.00%

'

'

'

'

'

'

'

'

'

'

'

Borrowing base, maximum amount added to certain eligible accounts

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowing base, maximum amount added to other inventories

'

'

'

'

'

'

'

'

'

'

'

'

4,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lines of credit

12,155,253

'

40,211,429

'

'

'

'

'

'

'

'

'

12,155,253

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

6,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Eligible collateral accounts receivable

'

'

'

'

'

'

'

'

'

'

'

'

9,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Eligible collateral inventory

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility, interest rate description

'

'

'

'Delayed Draw Loan bore interest at a floating rate equal to three-month LIBOR plus 10.5% per annum.

'

'

'

'

'

'

'

'

'ABL bear interest at a floating rate equal to one-month LIBOR plus 4.0% per annum.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility, percentage added to LIBOR

'

'

'

10.50%

'

'

'

'

'

'

'

'

4.00%

'

'

'

'

'

12.00%

'

'

'

'

'

'

'

'

'

'

Credit facility interest rate

'

'

'

'

'

'

'

'

'

'

'

'

4.16%

'

'

'

'

'

'

12.24%

'

'

'

'

'

'

'

'

'

Amendment No. 1 to the FCC ABL

'

'

'

'

'

'

'

'

'

'

'

'gives rise to the entry or filing of a judgment, order or award for the payment of $250,000 or more (which amount is not covered by insurance) against the Company and (i) within 45 days after the entry of such judgment, order or award (a) such judgment, order or award is not discharged, satisfied, vacated or bonded pending appeal, or (b) a stay of enforcement thereof is not in effect; (ii) enforcement proceedings with respect to such judgment have been commenced, or (iii) any person becomes a lien creditor (as defined in the Uniform Commercial Code) of the Company in connection with the Geveran Suit.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss Contingency, Range of Possible Loss, Minimum

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss Contingency, Action After Judgment, Maximum Period

'

'

'

'

'

'

'

'

'

'

'

'45 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

Additional Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

Term loan, balance amount

27,460,185

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

27,460,185

'

'

'

'

'

'

'

'

'

Accretion of discount on term loan

473,935

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

195,000

474,000

725,000

'

'

3,200,000

'

474,000

Accrued interest

381,611

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

382,000

'

'

'

'

'

'

'

'

'

Number of common shares into which warrants exercisable or exercised

185,578,750

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

Warrant exercise price per share of common stock

$0.72

'

'

'

'

'

'

'

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.95

'

Warrants expire date

'

'

'

'

'

'

'

19-Feb-24

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19-Feb-24

'

'

Fair value of warrant liabilities

'

'

'

'

'

'

'

'

3,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,200,000

'

Change in fair value of warrants

'

'

'

'

'

1,800,000

1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

1,800,000

'

'

'

Debt issuance costs at fair value

6,000,000

'

'

'

'

'

'

'

'

2,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deemed dividends

'

'

'

'

571,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Standby letter of credit

'

'

'

'

'

'

'

'

'

'

$25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Debt issuance costs at fair value	$6,000,000
Pegasus Guaranty [Member]	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'
Debt issuance costs at fair value	$2,800,000

Fair_Value_Measurements_Compan

Fair Value Measurements - Company's Financial Assets and Liabilities that were Accounted for at Fair Value on a Recurring Basis (Detail) (Fair Value Measurements [Member], Significant Unobservable Inputs Level 3 [Member], USD $)	Sep. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	$8,969,789
Pegasus Commitment [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Assets (Recurring)	1,040,000
Riverwood Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	3,256,653
September 2012 Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	1,040,000
Pegasus Warrant [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	1,800,000
THD Warrant [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	114,443
Medley Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	1,323,312
Pegasus Guaranty Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	$1,435,381

Fair_Value_Measurements_Reconc

Fair Value Measurements - Reconciliation of the Beginning and Ending Balances for Assets and Liabilities that were Accounted for at Fair Value on a Recurring Basis (Detail) (Significant Unobservable Inputs Level 3 [Member], USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	($7,767,711)	($7,960,705)
Realized and unrealized gains (losses) included in net loss	-18,721,128	1,320,753
Purchases, sales, issuances and settlements	-19,012,674	-3,700,000
Transfers in or out of Level 3	37,571,724	0
Ending balance	-7,929,789	-10,339,952
Pegasus Commitment [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	1,407,335	1,360,000
Realized and unrealized gains (losses) included in net loss	-367,335	240,000
Ending balance	1,040,000	1,600,000
Riverwood Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	-5,002,664	-7,960,705
Realized and unrealized gains (losses) included in net loss	1,746,011	1,320,753
Ending balance	-3,256,653	-6,639,952
September 2012 Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	-1,407,335	-1,360,000
Realized and unrealized gains (losses) included in net loss	367,335	-240,000
Ending balance	-1,040,000	-1,600,000
Pegasus Warrant [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	-2,765,047	0
Realized and unrealized gains (losses) included in net loss	965,047	'
Purchases, sales, issuances and settlements	'	-3,700,000
Ending balance	-1,800,000	-3,700,000
THD Warrant [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	0	'
Realized and unrealized gains (losses) included in net loss	-39,867	'
Transfers in or out of Level 3	-74,576	'
Ending balance	-114,443	'
Series J Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	0	'
Realized and unrealized gains (losses) included in net loss	-25,140,561	'
Purchases, sales, issuances and settlements	-12,505,739	'
Transfers in or out of Level 3	37,646,300	'
Ending balance	0	'
Medley Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	0	'
Realized and unrealized gains (losses) included in net loss	1,847,049	'
Purchases, sales, issuances and settlements	-3,170,361	'
Ending balance	-1,323,312	'
Pegasus Guaranty Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	0	'
Realized and unrealized gains (losses) included in net loss	1,901,193	'
Purchases, sales, issuances and settlements	-3,336,574	'
Ending balance	($1,435,381)	'

Series_J_Redeemable_Convertibl1

Series J Redeemable Convertible Preferred Stock - Additional Information (Detail) (USD $)

0 Months Ended

6 Months Ended

9 Months Ended

0 Months Ended

2 Months Ended

3 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

2 Months Ended

9 Months Ended

2 Months Ended

2 Months Ended

2 Months Ended

2 Months Ended

Sep. 25, 2012

Jun. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Mar. 07, 2014

Apr. 14, 2014

Mar. 07, 2014

Apr. 14, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 11, 2013

Sep. 11, 2013

Jan. 03, 2014

Jan. 03, 2014

Jan. 03, 2014

Sep. 11, 2013

Mar. 07, 2014

Nov. 18, 2013

Sep. 30, 2014

Dec. 31, 2013

Mar. 07, 2014

Mar. 07, 2014

Nov. 18, 2013

Jan. 03, 2014

Mar. 07, 2014

Nov. 18, 2013

Sep. 30, 2014

Jan. 09, 2014

Jan. 03, 2014

Mar. 07, 2014

Nov. 18, 2013

Jan. 03, 2014

Mar. 07, 2014

Nov. 18, 2013

Mar. 07, 2014

Jan. 09, 2014

Common Stock [Member]

Series J Issuance [Member]

Series J Warrants [Member]

Series J Warrants [Member]

Series J Warrants [Member]

Series J Warrants [Member]

Series J Warrants [Member]

Pegasus Warrant [Member]

Pegasus Warrant [Member]

Pegasus Warrant [Member]

Pegasus Warrant [Member]

PCA Holdings [Member]

Riverwood Holdings [Member]

LSGC Holdings [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Common Stock [Member]

Stockholders' Equity, Total [Member]

Series J Issuance [Member]

Series J Issuance [Member]

Series J Issuance [Member]

Series J Warrants [Member]

LSGC Holdings II, LLC [Member]

LSGC Holdings II, LLC [Member]

LSGC Holdings II, LLC [Member]

PCA Holdings [Member]

PCA Holdings [Member]

PCA Holdings [Member]

PCA Holdings [Member]

PCA Holdings [Member]

Riverwood Holdings [Member]

Riverwood Holdings [Member]

Riverwood Holdings [Member]

other accredited investors [Member]

other accredited investors [Member]

Zouk [Member]

Zouk [Member]

Series J Issuance [Member]

Temporary Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000

'

'

'

6,000

13,657

'

14,000

2,500

'

'

'

2,860

2,394

'

45

1,449

2,570

'

Preferred stock issued, par value per share

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares or units issued, price per share or unit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds

$49,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,500,000

$20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued to Holdings II, in consideration for advisory services

'

'

'

'

1,750,342

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Optional Conversion Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'(a) the Stated Value of such shares of Series J Preferred Stock by (b) the $0.95 conversion price, subject to certain adjustments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.95

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liquidation Amount, preference

'

$2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liquidation Amount

'

'The "Liquidation Amount" of each share of Series J Preferred Stock is equal to the greater of (a) the fair market value of the Optional Conversion Shares and (b) an amount equal to the product obtained by multiplying (A) the Stated Value by (B) 2.0.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred units issued as Series J Securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,475

'

'

'

'

'

'

6,000

'

'

8,000

4,000

2,000

'

'

2,860

'

'

'

2,570

Right to purchase common stock

'

'

'

'

'

'

'

2,650

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common shares

'

'

185,578,750

'

'

120,508,750

'

'

'

'

'

'

'

10,000,000

'

6,625,000

6,344,100

36,191,050

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,475

20,000

45,475

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional paid-in capital

'

'

332,161,145

331,199,891

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercise price per share of common stock

'

'

$0.72

'

'

'

'

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant liabilities

'

'

'

'

'

'

'

'

'

12,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of warrants

'

'

'

'

'

'

994,000

'

-25,100,000

'

'

1,900,000

965,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration risk, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.76%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total equity value

'

'

'

'

'

'

'

'

'

'

'

'

'

$570,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pegasus Warrant expiration date

'

'

'

'

'

'

'

'

'

'

'

'

25-May-22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Series_H_and_Series_I_Redeemab1

Series H and Series I Redeemable Convertible Preferred Stock - Additional Information (Detail) (USD $)

0 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

Sep. 25, 2012

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 25, 2012

25-May-12

Sep. 30, 2014

Dec. 31, 2013

25-May-12

25-May-12

25-May-12

25-May-12

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

25-May-12

25-May-12

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 25, 2012

Sep. 25, 2012

Sep. 25, 2012

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Series H Redeemable Convertible Preferred Stock [Member]

Series H Redeemable Convertible Preferred Stock [Member]

Series H Redeemable Convertible Preferred Stock [Member]

Series H Redeemable Convertible Preferred Stock [Member]

Series I Redeemable Convertible Preferred Stock [Member]

Series I Redeemable Convertible Preferred Stock [Member]

Series I Redeemable Convertible Preferred Stock [Member]

Series H And I Redeemable Convertible Preferred Stock [Member]

Series H And I Redeemable Convertible Preferred Stock [Member]

Riverwood Warrants [Member]

Riverwood Warrants [Member]

Riverwood Warrants [Member]

Riverwood Warrants [Member]

Riverwood Warrants [Member]

Riverwood Warrants [Member]

Riverwood Warrants [Member]

September 2012 Warrants [Member]

September 2012 Warrants [Member]

September 2012 Warrants [Member]

September 2012 Warrants [Member]

September 2012 Warrants [Member]

September 2012 Warrants [Member]

September 2012 Warrants [Member]

Pegasus Commitment [Member]

Pegasus Commitment [Member]

Pegasus Commitment [Member]

Pegasus Commitment [Member]

Stockholders' Equity, Total [Member]

Portman [Member]

Series H Redeemable Convertible Preferred Stock [Member]

Series H Redeemable Convertible Preferred Stock [Member]

Cleantech A [Member]

Cleantech B [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of preferred stock

'

'

113,609

113,609

49,000

60,705

62,365

62,365

6,364

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares or units issued, price per share or unit

'

'

'

'

$1,000

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds

$49,000,000

'

'

'

'

'

'

'

'

$67,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Right to purchase an aggregate common stock

'

'

'

'

'

'

'

'

'

'

'

18,092,511

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

3,406,041

593,959

'

'

'

'

Change in redemption value

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant was issued to Riverwood Management

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25-May-12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration risk, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

Equity value of company exceeds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

570,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25-May-22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of commitment shares

'

'

'

'

'

'

'

'

'

'

'

'

$3,400,000

($2,100,000)

$1,700,000

$1,300,000

'

'

$960,000

$320,000

$367,000

$240,000

'

'

'

$960,000

$320,000

$367,000

$240,000

Number of days available for redemption of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 days

'

'

'

'

'

'

'

'

Exercise price of common stock per share

'

$0.72

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

0 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

Aug. 12, 2013

Mar. 22, 2013

Jan. 02, 2013

Sep. 30, 2014

Jun. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Aug. 28, 2014

Aug. 27, 2014

Dec. 31, 2012

26-May-12

25-May-12

Dec. 31, 2011

Jan. 13, 2011

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Directors [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Scientific Advisory Board [Member]

Scientific Advisory Board [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Supply Commitment [Member]

September 2012 Warrants [Member]

September 2012 Warrants [Member]

September 2012 Warrants [Member]

September 2012 Warrants [Member]

THD Warrant [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Fair Market Value of Warrants [Member]

Minimum [Member]

Maximum [Member]

Customer Concentration Risk [Member]

THD Warrant [Member]

THD Warrant [Member]

THD Warrant [Member]

THD Warrant [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expense related to restricted stock awards

'

'

'

'

'

$221,000

$238,000

$412,000

$238,000

$26,000

$31,000

$49,000

$119,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option expense

'

'

'

'

'

'

0

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued for compensation package

'

192,308

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

Common stock, Purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2

'

'

'

'

'

'

Strategic Purchasing Agreement date with The Home Depot to supply LED retrofit lamps and fixtures

'

'

'

'

23-Jul-10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Base date to exercise price of warrant

'

'

'

'

23-Jul-10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock vested shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration risk, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting date of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9-Oct-15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-14

31-Dec-15

Long- term purchase commitment additional extension time period, years

'3 years

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long- term purchase commitment, time period, years

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price per share of common stock

'

'

'

$0.72

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.37

$1.95

'

$1.95

$2

'

'

'

'

'

'

'

'

Number of common stock shares into which warrant exercisable or exercised

'

'

'

185,578,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,321,347

5,123,715

'

5,123,715

5,000,000

'

'

'

'

'

'

'

'

Shares issuable pursuant to warrant vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

2,928,538

'

'

1,494,269

'

'

1,494,269

'

'

'

'

'

'

'

Total equity value of company

'

'

'

570,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue (increase) reduction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

960,000

320,000

367,000

240,000

'

'

'

'

'

'

'

'

'

'

38,000

9,000

100,000

23,000

'

'

Fair value of warrants liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Warrants for Purchase of Common Stock (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Class of Warrant or Right [Line Items]	'
Exercise Price	0.72
Number of common shares	185,578,750
Investors in Rights Offering [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'Series D Warrants
Number of common shares	825,634
Expiration Date, period start	'March 3, 2022
Expiration Date, period end	'April 19, 2022
Investors in Rights Offering [Member] | Minimum [Member]	'
Class of Warrant or Right [Line Items]	'
Exercise Price	4.21
Investors in Rights Offering [Member] | Maximum [Member]	'
Class of Warrant or Right [Line Items]	'
Exercise Price	4.23
THD [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'Purchasing agreement
Exercise Price	1.5
Number of common shares	7,321,347
Expiration Date, period start	'December 31, 2,014
Expiration Date, period end	'December 31, 2,018
RW LSG Management Holdings LLC [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'Riverwood Warrants
Number of common shares	12,664,760
Exercise Price, Description	'Variable
Expiration Date, period end	'May 25, 2022
Certain Other Investors [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'Riverwood Warrants
Number of common shares	5,427,751
Exercise Price, Description	'Variable
Expiration Date, period end	'May 25, 2022
Cleantech Europe II (A) LP [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'September 2012 Warrants
Exercise Price	0.72
Number of common shares	3,406,041
Expiration Date, period end	'September 25, 2022
Cleantech Europe II (B) LP [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'September 2012 Warrants
Exercise Price	0.72
Number of common shares	593,959
Expiration Date, period end	'September 25, 2022
Portman Limited [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'September 2012 Warrants
Exercise Price	0.72
Number of common shares	4,000,000
Expiration Date, period end	'September 25, 2022
Aquillian Investments LLC [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'Private Placement Series H
Exercise Price	1.18
Number of common shares	830,508
Expiration Date, period end	'September 25, 2017
Pegasus [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'Pegasus Warrant
Number of common shares	10,000,000
Exercise Price, Description	'Variable
Expiration Date, period end	'May 25, 2022
Investors in Series J Follow-On Offering Series J Warrants [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'Series J Warrants
Exercise Price	0.001
Number of common shares	120,508,750
Expiration Date, period start	'January 3, 2019
Expiration Date, period end	'August 27, 2019
Medley Capital Corporation [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'Medley Debt
Exercise Price	0.95
Number of common shares	10,000,000
Expiration Date, period end	'February 19, 2024
Pegasus Guaranty [Member]	'
Class of Warrant or Right [Line Items]	'
Reason for Issuance	'Pegasus Guaranty Warrants
Exercise Price	0.5
Number of common shares	10,000,000
Expiration Date, period end	'February 19, 2024

Earnings_Loss_Per_Share_Additi

Earnings (Loss) Per Share - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jan. 17, 2012	Jan. 17, 2012
					Series J Warrants [Member]	Series J Warrants [Member]	Class C Interests [Member]	Settlement of Repurchase Obligation [Member]
							Minimum [Member]
Earnings Per Common Share [Line Items]	'	'	'	'	'	'	'	'
Preferred equity issued	'	'	'	'	'	'	$80	'
Surrendering common stock	'	'	'	'	'	'	'	3,750,000
Redeemable preferred stock	'	'	'	'	'	'	'	15,000,000
Method used to compute net loss per share of noncontrolling shareholders and controlling shareholders common stock	'Two-class method	'Two-class method	'Two-class method	'Two-class method	'	'	'	'
Common stock equivalents outstanding	177,100,000	190,400,000	174,400,000	186,800,000	'	'	'	'
Warrants exercise price per share of common stock	$0.72	'	$0.72	'	$0.00	$0.00	'	'

Earnings_Loss_Per_Share_Comput

Earnings (Loss) Per Share - Computation of Basic and Diluted Net Loss Per Share of Common Stock (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Controlling Shareholders [Member]	'	'	'	'
Basic and diluted net income per share:	'	'	'	'
Undistributed net loss	'	'	($76,901,951)	($77,798,508)
Net loss attributable to common stock	-1,686,077	-21,156,773	43,394,934	47,896,411
Undistributed net loss	-11,257,581	-51,050,064	'	'
Basic and diluted weighted average number of common shares outstanding	255,194,735	170,672,339	220,629,709	170,645,985
Basic and diluted net loss per common share	($0.04)	($0.30)	($0.35)	($0.46)
Controlling Shareholders [Member] | Pegasus Warrant [Member]	'	'	'	'
Basic and diluted net income per share:	'	'	'	'
Deemed dividends	'	'	570,574	0
Controlling Shareholders [Member] | Series J Redeemable Convertible Preferred Stock [Member]	'	'	'	'
Basic and diluted net income per share:	'	'	'	'
Deemed dividends	9,571,504	17,910,579	-34,077,591	-17,915,855
Controlling Shareholders [Member] | Series H And I Redeemable Convertible Preferred Stock [Member]	'	'	'	'
Basic and diluted net income per share:	'	'	'	'
Deemed dividends	0	11,982,712	0	-11,986,242
Noncontrolling Shareholders [Member]	'	'	'	'
Basic and diluted net income per share:	'	'	'	'
Undistributed net loss	'	'	-19,191,361	-15,954,964
Net loss attributable to common stock	-416,499	-4,346,354	10,430,121	9,822,624
Undistributed net loss	-2,780,873	-10,487,500	'	'
Basic and diluted weighted average number of common shares outstanding	63,038,781	35,062,174	53,029,108	34,996,177
Basic and diluted net loss per common share	($0.04)	($0.30)	($0.36)	($0.46)
Noncontrolling Shareholders [Member] | Pegasus Warrant [Member]	'	'	'	'
Basic and diluted net income per share:	'	'	'	'
Deemed dividends	'	'	-570,574	0
Noncontrolling Shareholders [Member] | Series J Redeemable Convertible Preferred Stock [Member]	'	'	'	'
Basic and diluted net income per share:	'	'	'	'
Deemed dividends	2,364,374	3,679,470	-8,190,666	-3,674,194
Noncontrolling Shareholders [Member] | Series H And I Redeemable Convertible Preferred Stock [Member]	'	'	'	'
Basic and diluted net income per share:	'	'	'	'
Deemed dividends	$0	$2,461,676	$0	($2,458,146)

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Jan. 03, 2014

Mar. 07, 2014

Sep. 30, 2014

Sep. 25, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

25-May-12

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2012

Sep. 30, 2012

Jan. 03, 2014

Jan. 09, 2014

Sep. 30, 2014

Feb. 19, 2014

Sep. 30, 2014

Sep. 30, 2014

Jan. 09, 2014

Sep. 30, 2014

Jan. 03, 2014

Jan. 03, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Pegasus Guaranty [Member]

Pegasus Guaranty [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Pegasus Support Services Agreement [Member]

Pegasus Support Services Agreement [Member]

Riverwood Support Services Agreement [Member]

Riverwood Support Services Agreement [Member]

Riverwood Support Services Agreement [Member]

Riverwood Support Services Agreement [Member]

Riverwood Support Services Agreement [Member]

Riverwood Support Services Agreement [Member]

Zouk Support Services Agreement [Member]

Zouk Support Services Agreement [Member]

Zouk Support Services Agreement [Member]

Riverwood Holdings [Member]

Zouk [Member]

Pegasus Capital [Member]

Pegasus Guaranty Warrants [Member]

Pegasus Guaranty Warrants [Member]

Pegasus Guaranty Warrants [Member]

PCA Holdings [Member]

PCA Holdings [Member]

PCA Holdings [Member]

LSGC Holdings II, LLC [Member]

T&M Protection Resources [Member]

T&M Protection Resources [Member]

T&M Protection Resources [Member]

T&M Protection Resources [Member]

Series H Redeemable Convertible Preferred Stock [Member]

Series H Redeemable Convertible Preferred Stock [Member]

Series H Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Implied Interest Rate Analysis [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Maximum [Member]

Maximum [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Due to related parties

'

'

'

'

'

'

'

'

$125,000

'

'

'

'

'

$20,000

'

'

$100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership percentage of subsidiary held in parent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

87.80%

'

'

'

'

'

'

'

'

'

'

'

Services agreement, expiration terms

'

'

'

'

'

'

'

'

'The Pegasus Support Services Agreement expires upon the earlier of (i) June 30, 2017; (ii) a Change of Control (as defined therein) or (iii) a QPO. During the first 30 days of any calendar quarter, the Company has the right to terminate the Pegasus Support Services Agreement, effective immediately upon written notice to Pegasus Capital.

'

'

'

'The Riverwood Support Services Agreement expires upon the earlier of: (i) May 25, 2022, (ii) such date that Riverwood Management and/or its affiliates directly or indirectly beneficially own less than 37.5% of the shares of Series H Preferred Stock purchased pursuant to the Series H and I Preferred Offering, on an as-converted basis (together with any shares of Common Stock issued upon conversion thereof); (iii) such date that the Company and Riverwood may mutually agree in writing (iv) a Change of Control (as defined in the Riverwood Warrant) or (v) a QPO. In addition, the Company has brought in several employees of Riverwood to provide consulting services. During the three and nine months ended September 30, 2014, the Company incurred $11,000, and $880,000, respectively, of consulting fees for services provided by Riverwood, included in selling, distribution and administrative expense. During the three and nine months ended September 30, 2013, the Company incurred $656,000, and $1.7 million, respectively, of consulting fees for services provided by Riverwood, included in selling, distribution and administrative expense.

'

'

'

'The Zouk Support Services Agreement expires upon the earlier of (i) September 25, 2022; (ii) such date that Zouk and/or its affiliates directly or indirectly beneficially own less than 37.5% of the shares of Series H Preferred Stock purchased pursuant to the September 2012 Preferred Offering, on an as-converted basis; (iii) such date that the Company and Zouk may mutually agree in writing; (iv) a Change of Control (as defined in the September 2012 Warrants) and (v) a QPO.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of shares owned in preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37.50%

'

'

37.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future Payment to Riverwood Holdings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related party service consulting fees

8,385,811

11,749,901

27,679,750

38,171,922

'

'

'

'

'

'

2,000

656,000

872,000

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fee Waiver Letter Agreement

'

'

'

'

'

'

'

'

'

'Parties agreed to suspend payment of the fees payable in connection with their respective support services or other agreements between the Company and such parties until revoked by their unanimous written consent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,300,000

'

'

'

'

'

'

'

'

'

'

Debt issuance costs at fair value

'

'

6,000,000

'

'

2,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,800,000

'

'

'

'

'

'

'

'

Deemed dividends

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

571,000

'

'

'

'

'

'

'

'

'

Non-cash related party interest expense

138,300

'

338,067

'

138,000

338,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred units issued as Series J Securities

'

'

'

'

'

'

'

25,475

'

'

'

'

'

'

'

'

'

'

'

2,860

2,570

'

'

'

'

4,000

8,000

2,000

6,000

'

'

'

'

Proceeds from sale of series J preferred units

'

'

'

'

'

'

8,000,000

'

'

'

'

'

'

'

'

'

'

'

'

2,900,000

2,600,000

'

'

'

'

4,000,000

8,000,000

'

'

'

'

'

'

Related party expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$9,000

$0

$9,000

$15,000

Concentrations_of_Credit_Risk_

Concentrations of Credit Risk - Additional Information (Detail)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Customer

Customer

Customer

Customer

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer

Customer

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Concentration Risk [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of customers

1

1

1

1

'

'

'

'

1

1

'

'

Concentration risk, percentage

'

'

'

'

82.00%

56.00%

78.00%

52.00%

'

'

77.00%

55.00%

Restructuring_Expense_Summary_

Restructuring Expense - Summary of Restructuring Expense and Related Charges (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Multi-year initiatives and related charges	$2,466,505	$55,275	$2,672,350	$184,107
Multi-year initiatives and related charges	'	'	2,672,350	184,107
Facility Closing [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Multi-year initiatives and related charges	'	'	2,558,072	0
Organization Optimization Initiative [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Multi-year initiatives and related charges	'	'	114,278	53,550
Mexico [Member] | Facility Closing [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Multi-year initiatives and related charges	'	'	$0	$130,557

Restructuring_Expense_Summary_1

Restructuring Expense - Summary of Restructuring Expense and Related Charges (Parenthetical) (Detail) (USD $)	3 Months Ended		9 Months Ended			1 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	31-May-12
					Multi Year Initiatives [Member]	Multi Year Initiatives [Member]
						United States [Member]
						Employee
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring costs	$2,466,505	$55,275	$2,672,350	$184,107	$446,000	'
Number of employees replaced	'	'	'	'	'	10

Restructuring_Expense_Accrued_

Restructuring Expense - Accrued Liability Associated with the Restructuring Charges (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Restructuring Cost and Reserve [Line Items]	'
Accrued liability, Beginning Balance	$976,788
Charges	2,144,746
Reversals	-94,214
Payments	-1,704,889
Accrued liability, Ending Balance	1,322,431
Organization Optimization Initiative [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Accrued liability, Beginning Balance	699,832
Charges	2,026,786
Reversals	0
Payments	-1,511,513
Accrued liability, Ending Balance	1,215,105
Other Exit Costs [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Accrued liability, Beginning Balance	276,956
Charges	117,960
Reversals	-94,214
Payments	-193,376
Accrued liability, Ending Balance	$107,326

Restructuring_Expense_Addition

Restructuring Expense - Additional Information (Detail) (USD $)	Sep. 30, 2014
In Millions, unless otherwise specified
Restructuring Costs [Abstract]	'
Remaining accrual	$1.30

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Oct. 30, 2012	Jun. 22, 2012	Sep. 30, 2014	Jun. 22, 2012	10-May-11
Loss Contingencies [Line Items]	'	'	'	'	'
Filed a lawsuit	'	'June 22, 2012	'	'	'
Order transferring the lawsuit to the Ninth Judicial Circuit	'Orange County, Florida	'Broward County, Florida	'	'	'
A stockholder of the Company, filed a lawsuit	'Geveran Investments Limited	'	'	'	'
Named as defendants	'Lighting Science Group Corp., et al.	'	'	'	'
Alleged	'	'	'	'	'
Loss Contingency, Expected Trial Commencement	'2014-09	'	'	'	'
Litigation expenses	'	'	28-Aug-14	'	'
Litigation, awarded value	'	'	25	'	'
Geveran Investments Ltd. [Member]	'	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'	'
Geveran seeks rescission	25	'	'	'	'
Common stock, issued value	'	'	'	'	$25
Appeal period against judgment	'	'	'30 days	'	'